-
1
-
-
84855894652
-
Targeting the MAPK-RAS-RAF signaling pathway in cancer therapy
-
22239440 10.1517/14728222.2011.645805 1:CAS:528:DC%2BC38Xos1Wktw%3D%3D
-
Santarpia L, Lippman SM, El-Naggar AK (2012) Targeting the MAPK-RAS-RAF signaling pathway in cancer therapy. Expert Opin Ther Targets 16:103-119
-
(2012)
Expert Opin Ther Targets
, vol.16
, pp. 103-119
-
-
Santarpia, L.1
Lippman, S.M.2
El-Naggar, A.K.3
-
2
-
-
68249093818
-
Targeting the phosphoinositide 3-kinase pathway in cancer
-
19644473 10.1038/nrd2926 1:CAS:528:DC%2BD1MXpt1Wgtb4%3D
-
Liu P, Cheng H, Roberts TM, Zhao JJ (2009) Targeting the phosphoinositide 3-kinase pathway in cancer. Nat Rev Drug Discov 8:627-644
-
(2009)
Nat Rev Drug Discov
, vol.8
, pp. 627-644
-
-
Liu, P.1
Cheng, H.2
Roberts, T.M.3
Zhao, J.J.4
-
3
-
-
79960237399
-
Therapeutic resistance resulting from mutations in Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR signaling pathways
-
21302297 10.1002/jcp.22647 1:CAS:528:DC%2BC3MXhtVKksrfM
-
McCubrey JA, Steelman LS, Kempf CR, Chappell WH, Abrams SL, Stivala F, Malaponte G, Nicoletti F, Libra M, Basecke J, Maksimovic-Ivanic D, Mijatovic S, Montalto G, Cervello M, Cocco L, Martelli AM (2011) Therapeutic resistance resulting from mutations in Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR signaling pathways. J Cell Physiol 226:2762-2781
-
(2011)
J Cell Physiol
, vol.226
, pp. 2762-2781
-
-
McCubrey, J.A.1
Steelman, L.S.2
Kempf, C.R.3
Chappell, W.H.4
Abrams, S.L.5
Stivala, F.6
Malaponte, G.7
Nicoletti, F.8
Libra, M.9
Basecke, J.10
Maksimovic-Ivanic, D.11
Mijatovic, S.12
Montalto, G.13
Cervello, M.14
Cocco, L.15
Martelli, A.M.16
-
4
-
-
77949881462
-
The PI3K pathway as drug target in human cancer
-
20085938 10.1200/JCO.2009.25.3641 1:CAS:528:DC%2BC3cXktF2lt7w%3D
-
Courtney KD, Corcoran RB, Engelman JA (2010) The PI3K pathway as drug target in human cancer. J Clin Oncol 28:1075-1083
-
(2010)
J Clin Oncol
, vol.28
, pp. 1075-1083
-
-
Courtney, K.D.1
Corcoran, R.B.2
Engelman, J.A.3
-
6
-
-
34547209343
-
Roles of the Raf/MEK/ERK pathway in cell growth, malignant transformation and drug resistance
-
17126425 10.1016/j.bbamcr.2006.10.001 1:CAS:528:DC%2BD2sXosFyksbk%3D
-
McCubrey JA, Steelman LS, Chappell WH, Abrams SL, Wong EW, Chang F, Lehmann B, Terrian DM, Milella M, Tafuri A, Stivala F, Libra M, Basecke J, Evangelisti C, Martelli AM, Franklin RA (2007) Roles of the Raf/MEK/ERK pathway in cell growth, malignant transformation and drug resistance. Biochim Biophys Acta 1773:1263-1284
-
(2007)
Biochim Biophys Acta
, vol.1773
, pp. 1263-1284
-
-
McCubrey, J.A.1
Steelman, L.S.2
Chappell, W.H.3
Abrams, S.L.4
Wong, E.W.5
Chang, F.6
Lehmann, B.7
Terrian, D.M.8
Milella, M.9
Tafuri, A.10
Stivala, F.11
Libra, M.12
Basecke, J.13
Evangelisti, C.14
Martelli, A.M.15
Franklin, R.A.16
-
7
-
-
79958026380
-
The Ras-ERK and PI3K-mTOR pathways: Cross-talk and compensation
-
21531565 10.1016/j.tibs.2011.03.006 1:CAS:528:DC%2BC3MXnsVOqs7k%3D
-
Mendoza MC, Er EE, Blenis J (2011) The Ras-ERK and PI3K-mTOR pathways: cross-talk and compensation. Trends Biochem Sci 36:320-328
-
(2011)
Trends Biochem Sci
, vol.36
, pp. 320-328
-
-
Mendoza, M.C.1
Er, E.E.2
Blenis, J.3
-
8
-
-
0028074316
-
Phosphatidylinositol-3-OH kinase as a direct target of Ras
-
8052307 10.1038/370527a0 1:CAS:528:DyaK2cXmsV2hs7w%3D
-
Rodriguez-Viciana P, Warne PH, Dhand R, Vanhaesebroeck B, Gout I, Fry MJ, Waterfield MD, Downward J (1994) Phosphatidylinositol-3-OH kinase as a direct target of Ras. Nature 370:527-532
-
(1994)
Nature
, vol.370
, pp. 527-532
-
-
Rodriguez-Viciana, P.1
Warne, P.H.2
Dhand, R.3
Vanhaesebroeck, B.4
Gout, I.5
Fry, M.J.6
Waterfield, M.D.7
Downward, J.8
-
9
-
-
34547645033
-
Identification of S664 TSC2 phosphorylation as a marker for extracellular signal-regulated kinase mediated mTOR activation in tuberous sclerosis and human cancer
-
17671177 10.1158/0008-5472.CAN-06-4798 1:CAS:528:DC%2BD2sXosVemsb4%3D
-
Ma L, Teruya-Feldstein J, Bonner P, Bernardi R, Franz DN, Witte D, Cordon-Cardo C, Pandolfi PP (2007) Identification of S664 TSC2 phosphorylation as a marker for extracellular signal-regulated kinase mediated mTOR activation in tuberous sclerosis and human cancer. Cancer Res 67:7106-7112
-
(2007)
Cancer Res
, vol.67
, pp. 7106-7112
-
-
Ma, L.1
Teruya-Feldstein, J.2
Bonner, P.3
Bernardi, R.4
Franz, D.N.5
Witte, D.6
Cordon-Cardo, C.7
Pandolfi, P.P.8
-
10
-
-
0033607633
-
Phosphorylation and regulation of Raf by Akt (protein kinase B)
-
10576742 10.1126/science.286.5445.1741 1:CAS:528:DyaK1MXnsl2nsLk%3D
-
Zimmermann S, Moelling K (1999) Phosphorylation and regulation of Raf by Akt (protein kinase B). Science 286:1741-1744
-
(1999)
Science
, vol.286
, pp. 1741-1744
-
-
Zimmermann, S.1
Moelling, K.2
-
11
-
-
84856253626
-
Cross-talk between mitogenic Ras/MAPK and survival PI3K/Akt pathways: A fine balance
-
22260680 10.1042/BST20110609 1:CAS:528:DC%2BC38XhtFCqu7k%3D
-
Aksamitiene E, Kiyatkin A, Kholodenko BN (2012) Cross-talk between mitogenic Ras/MAPK and survival PI3K/Akt pathways: a fine balance. Biochem Soc Trans 40:139-146
-
(2012)
Biochem Soc Trans
, vol.40
, pp. 139-146
-
-
Aksamitiene, E.1
Kiyatkin, A.2
Kholodenko, B.N.3
-
12
-
-
79957983577
-
Targeting the PI3K/Akt/mTOR pathway - Beyond rapalogs
-
21317449
-
Markman B, Dienstmann R, Tabernero J (2010) Targeting the PI3K/Akt/mTOR pathway - beyond rapalogs. Oncotarget 1:530-543
-
(2010)
Oncotarget
, vol.1
, pp. 530-543
-
-
Markman, B.1
Dienstmann, R.2
Tabernero, J.3
-
13
-
-
79960605738
-
Targeting phosphatidylinositol 3 kinase (PI3K)-Akt beyond rapalogs
-
21547565 10.1007/s11523-011-0176-7
-
Ogita S, Lorusso P (2011) Targeting phosphatidylinositol 3 kinase (PI3K)-Akt beyond rapalogs. Target Oncol 6:103-117
-
(2011)
Target Oncol
, vol.6
, pp. 103-117
-
-
Ogita, S.1
Lorusso, P.2
-
14
-
-
84856071447
-
Phase I, dose-escalation study of BKM120, an oral pan-class i PI3K inhibitor, in patients with advanced solid tumors
-
22162589 10.1200/JCO.2011.36.1360 1:CAS:528:DC%2BC38XjsFCit70%3D
-
Bendell JC, Rodon J, Burris HA, de Jonge M, Verweij J, Birle D, Demanse D, De Buck SS, Ru QC, Peters M, Goldbrunner M, Baselga J (2012) Phase I, dose-escalation study of BKM120, an oral pan-class I PI3K inhibitor, in patients with advanced solid tumors. J Clin Oncol 30:282-290
-
(2012)
J Clin Oncol
, vol.30
, pp. 282-290
-
-
Bendell, J.C.1
Rodon, J.2
Burris, H.A.3
De Jonge, M.4
Verweij, J.5
Birle, D.6
Demanse, D.7
De Buck, S.S.8
Ru, Q.C.9
Peters, M.10
Goldbrunner, M.11
Baselga, J.12
-
15
-
-
0037264633
-
Targeting RAS signalling pathways in cancer therapy
-
12509763 10.1038/nrc969 1:CAS:528:DC%2BD38XpvVertbo%3D
-
Downward J (2003) Targeting RAS signalling pathways in cancer therapy. Nat Rev Cancer 3:11-22
-
(2003)
Nat Rev Cancer
, vol.3
, pp. 11-22
-
-
Downward, J.1
-
16
-
-
79959795786
-
Improved survival with vemurafenib in melanoma with BRAF V600E mutation
-
BRIM-3 Study Group 21639808 10.1056/NEJMoa1103782 1:CAS:528: DC%2BC3MXosVeitbs%3D
-
Chapman PB, Hauschild A, Robert C, Haanen JB, Ascierto P, Larkin J, Dummer R, Garbe C, Testori A, Maio M, Hogg D, Lorigan P, Lebbe C, Jouary T, Schadendorf D, Ribas A, O'Day SJ, Sosman JA, Kirkwood JM, Eggermont AM, Dreno B, Nolop K, Li J, Nelson B, Hou J, Lee RJ, Flaherty KT, McArthur GA, BRIM-3 Study Group (2011) Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med 364:2507-2516
-
(2011)
N Engl J Med
, vol.364
, pp. 2507-2516
-
-
Chapman, P.B.1
Hauschild, A.2
Robert, C.3
Haanen, J.B.4
Ascierto, P.5
Larkin, J.6
Dummer, R.7
Garbe, C.8
Testori, A.9
Maio, M.10
Hogg, D.11
Lorigan, P.12
Lebbe, C.13
Jouary, T.14
Schadendorf, D.15
Ribas, A.16
O'Day, S.J.17
Sosman, J.A.18
Kirkwood, J.M.19
Eggermont, A.M.20
Dreno, B.21
Nolop, K.22
Li, J.23
Nelson, B.24
Hou, J.25
Lee, R.J.26
Flaherty, K.T.27
McArthur, G.A.28
more..
-
17
-
-
84863673204
-
Improved survival with MEK inhibition in BRAF-mutated melanoma
-
METRIC Study Group 22663011 10.1056/NEJMoa1203421 1:CAS:528: DC%2BC38XhtFKjs7zN
-
Flaherty KT, Robert C, Hersey P, Nathan P, Garbe C, Milhem M, Demidov LV, Hassel JC, Rutkowski P, Mohr P, Dummer R, Trefzer U, Larkin JM, Utikal J, Dreno B, Nyakas M, Middleton MR, Becker JC, Casey M, Sherman LJ, Wu FS, Ouellet D, Martin AM, Patel K, Schadendorf D, METRIC Study Group (2012) Improved survival with MEK inhibition in BRAF-mutated melanoma. N Engl J Med 367:107-114
-
(2012)
N Engl J Med
, vol.367
, pp. 107-114
-
-
Flaherty, K.T.1
Robert, C.2
Hersey, P.3
Nathan, P.4
Garbe, C.5
Milhem, M.6
Demidov, L.V.7
Hassel, J.C.8
Rutkowski, P.9
Mohr, P.10
Dummer, R.11
Trefzer, U.12
Larkin, J.M.13
Utikal, J.14
Dreno, B.15
Nyakas, M.16
Middleton, M.R.17
Becker, J.C.18
Casey, M.19
Sherman, L.J.20
Wu, F.S.21
Ouellet, D.22
Martin, A.M.23
Patel, K.24
Schadendorf, D.25
more..
-
18
-
-
34547482919
-
Clinical experience of MEK inhibitors in cancer therapy
-
17194493 10.1016/j.bbamcr.2006.11.009 1:CAS:528:DC%2BD2sXosFyksbs%3D
-
Wang D, Boerner SA, Winkler JD, LoRusso PM (2007) Clinical experience of MEK inhibitors in cancer therapy. Biochim Biophys Acta 1773:1248-1255
-
(2007)
Biochim Biophys Acta
, vol.1773
, pp. 1248-1255
-
-
Wang, D.1
Boerner, S.A.2
Winkler, J.D.3
Lorusso, P.M.4
-
19
-
-
79958784935
-
Clinical safety and activity in a phase 1 study of CAL-101, an isoform-selective inhibitor of phosphatidylinositol 3-kinase p110d, in patients with relapsed or refractory non-Hodgkin lymphoma
-
(abstract #1777)
-
Kahl B, Byrd JC, Flinn IW, Wagner-Johnston N, Spurgeon S, Benson DM, Furman RR, Brown JR, Coutre S, Lannuttie B, Giese NA, Ulrich RG, Webb HK, Peterman S, Holes L, Yu AS (2010) Clinical safety and activity in a phase 1 study of CAL-101, an isoform-selective inhibitor of phosphatidylinositol 3-kinase p110d, in patients with relapsed or refractory non-Hodgkin lymphoma. 52nd ASH annual meeting and exposition (abstract #1777)
-
(2010)
52nd ASH Annual Meeting and Exposition
-
-
Kahl, B.1
Byrd, J.C.2
Flinn, I.W.3
Wagner-Johnston, N.4
Spurgeon, S.5
Benson, D.M.6
Furman, R.R.7
Brown, J.R.8
Coutre, S.9
Lannuttie, B.10
Giese, N.A.11
Ulrich, R.G.12
Webb, H.K.13
Peterman, S.14
Holes, L.15
Yu, A.S.16
-
20
-
-
84861992072
-
A phase i study evaluating GDC-0941, an oral phosphoinositide-3 kinase (PI3K) inhibitor
-
Moreno Garcia V, Baird RD, Shah KJ, Basu B, Tunariu N, Blanco M, Cassier PA, Pedersen JV, Puglisi M, Sarker D, Papadatos-Pastos D, Omlin AG, Biondo A, Ware JA, Koeppen H, Levy GG, Mazina KE, De Bono JS (2011) A phase I study evaluating GDC-0941, an oral phosphoinositide-3 kinase (PI3K) inhibitor, in patients with advanced solid tumors or multiple myeloma. ASCO Meeting Abstracts 29:3021
-
(2011)
Patients with Advanced Solid Tumors or Multiple Myeloma. ASCO Meeting Abstracts
, vol.29
, pp. 3021
-
-
Moreno Garcia, V.1
Baird, R.D.2
Shah, K.J.3
Basu, B.4
Tunariu, N.5
Blanco, M.6
Cassier, P.A.7
Pedersen, J.V.8
Puglisi, M.9
Sarker, D.10
Papadatos-Pastos, D.11
Omlin, A.G.12
Biondo, A.13
Ware, J.A.14
Koeppen, H.15
Levy, G.G.16
Mazina, K.E.17
De Bono, J.S.18
-
21
-
-
77956602070
-
First-in-human phase i study of the oral PI3K inhibitor BEZ235 in patients (pts) with advanced solid tumors
-
Burris H, Rodon J, Sharma S, Herbst RS, Tabernero J, Infante JR, Silva A, Demanse D, Hackl W, Baselga J (2010) First-in-human phase I study of the oral PI3K inhibitor BEZ235 in patients (pts) with advanced solid tumors. ASCO Meeting Abstracts 28:3005
-
(2010)
ASCO Meeting Abstracts
, vol.28
, pp. 3005
-
-
Burris, H.1
Rodon, J.2
Sharma, S.3
Herbst, R.S.4
Tabernero, J.5
Infante, J.R.6
Silva, A.7
Demanse, D.8
Hackl, W.9
Baselga, J.10
-
22
-
-
84876725174
-
Phase i study of intravenous PI3K inhibitor BAY 80-6946: Activity in patients (pts) with advanced solid tumors and non-Hodgkin lymphoma treated in MTD expansion cohorts
-
abstr 3019
-
Lotze MT, Appleman LJ, Ramanathan RK, Tolcher AW, Beeram M, Papadopoulos KP, Rasco DW, Weiss GJ, Mountz JM, Toledo FGS, Alvarez RJ, Oborski MJ, Rajagopalan P, Jeffers M, Roth D, Dubowy RL, Patnaik A (2012) Phase I study of intravenous PI3K inhibitor BAY 80-6946: activity in patients (pts) with advanced solid tumors and non-Hodgkin lymphoma treated in MTD expansion cohorts. J Clin Oncol 30 (suppl; abstr 3019)
-
(2012)
J Clin Oncol
, vol.30
, Issue.SUPPL.
-
-
Lotze, M.T.1
Appleman, L.J.2
Ramanathan, R.K.3
Tolcher, A.W.4
Beeram, M.5
Papadopoulos, K.P.6
Rasco, D.W.7
Weiss, G.J.8
Mountz, J.M.9
Toledo, F.G.S.10
Alvarez, R.J.11
Oborski, M.J.12
Rajagopalan, P.13
Jeffers, M.14
Roth, D.15
Dubowy, R.L.16
Patnaik, A.17
-
23
-
-
84878664337
-
First-in-patient study of PF-04691502, a small molecule intravenous dual inhibitor of PI3K and mTOR in patients with advanced cancer: Update on safety, efficacy, and pharmacology
-
2011 Nov 12-16; San Francisco, CA Philadelphia (PA): AACR; Mol Cancer Ther 10(11 Suppl):Abstract nr B163
-
Millham R, Houk B, Borzillo G, LoRusso P, Marburg L, Britten C, Wainberg Z, Adjei A, Grace D (2011) First-in-patient study of PF-04691502, a small molecule intravenous dual inhibitor of PI3K and mTOR in patients with advanced cancer: Update on safety, efficacy, and pharmacology. In: Proceedings of the AACR-NCI-EORTC international conference: molecular targets and cancer therapeutics; 2011 Nov 12-16; San Francisco, CA Philadelphia (PA): AACR; Mol Cancer Ther 10(11 Suppl):Abstract nr B163
-
(2011)
Proceedings of the AACR-NCI-EORTC International Conference: Molecular Targets and Cancer Therapeutics
-
-
Millham, R.1
Houk, B.2
Borzillo, G.3
Lorusso, P.4
Marburg, L.5
Britten, C.6
Wainberg, Z.7
Adjei, A.8
Grace, D.9
-
24
-
-
84878664337
-
First-in-patient study of PF-05212384, a small molecule intravenous dual inhibitor of PI3K and mTOR in patients with advanced cancer: Update on safety, efficacy, and pharmacology
-
2011 Nov 12-16; San Francisco, CA Philadelphia (PA): AACR; Mol Cancer Ther Abstract nr A167
-
Millham R, Houk B, Borzillo G, Tabernero T, Bell-McGuinn K, Bendell J, Molina J, Kwakm E, Shapiro G (2011) First-in-patient study of PF-05212384, a small molecule intravenous dual inhibitor of PI3K and mTOR in patients with advanced cancer: Update on safety, efficacy, and pharmacology. In: Proceedings of the AACR-NCI-eortc international conference: molecular targets and cancer therapeutics; 2011 Nov 12-16; San Francisco, CA Philadelphia (PA): AACR; Mol Cancer Ther 10(11 Suppl):Abstract nr A167
-
(2011)
Proceedings of the AACR-NCI-eortc International Conference: Molecular Targets and Cancer Therapeutics
, vol.10
, Issue.11 SUPPL.
-
-
Millham, R.1
Houk, B.2
Borzillo, G.3
Tabernero, T.4
Bell-Mcguinn, K.5
Bendell, J.6
Molina, J.7
Kwakm, E.8
Shapiro, G.9
-
25
-
-
79959283388
-
Multi-institutional phase II study of selumetinib in patients with metastatic biliary cancers
-
21519026 10.1200/JCO.2010.33.9473 1:CAS:528:DC%2BC3MXovFKqsbc%3D
-
Bekaii-Saab T, Phelps MA, Li X, Saji M, Goff L, Kauh JS, O'Neil BH, Balsom S, Balint C, Liersemann R, Vasko VV, Bloomston M, Marsh W, Doyle LA, Ellison G, Grever M, Ringel MD, Villalona-Calero MA (2011) Multi-institutional phase II study of selumetinib in patients with metastatic biliary cancers. J Clin Oncol 29:2357-2363
-
(2011)
J Clin Oncol
, vol.29
, pp. 2357-2363
-
-
Bekaii-Saab, T.1
Phelps, M.A.2
Li, X.3
Saji, M.4
Goff, L.5
Kauh, J.S.6
O'Neil, B.H.7
Balsom, S.8
Balint, C.9
Liersemann, R.10
Vasko, V.V.11
Bloomston, M.12
Marsh, W.13
Doyle, L.A.14
Ellison, G.15
Grever, M.16
Ringel, M.D.17
Villalona-Calero, M.A.18
-
26
-
-
14844285975
-
Multicenter phase II study of the oral MEK inhibitor, CI-1040, in patients with advanced non-small-cell lung, breast, colon, and pancreatic cancer
-
15483017 10.1200/JCO.2004.01.185 1:CAS:528:DC%2BD2cXhtFWqt77L
-
Rinehart J, Adjei AA, Lorusso PM, Waterhouse D, Hecht JR, Natale RB, Hamid O, Varterasian M, Asbury P, Kaldjian EP, Gulyas S, Mitchell DY, Herrera R, Sebolt-Leopold JS, Meyer MB (2004) Multicenter phase II study of the oral MEK inhibitor, CI-1040, in patients with advanced non-small-cell lung, breast, colon, and pancreatic cancer. J Clin Oncol 22:4456-4462
-
(2004)
J Clin Oncol
, vol.22
, pp. 4456-4462
-
-
Rinehart, J.1
Adjei, A.A.2
Lorusso, P.M.3
Waterhouse, D.4
Hecht, J.R.5
Natale, R.B.6
Hamid, O.7
Varterasian, M.8
Asbury, P.9
Kaldjian, E.P.10
Gulyas, S.11
Mitchell, D.Y.12
Herrera, R.13
Sebolt-Leopold, J.S.14
Meyer, M.B.15
-
27
-
-
84855487013
-
A Phase II, open-label, randomised study to assess the efficacy and safety of the MEK1/2 inhibitor AZD6244 (ARRY-142886) versus capecitabine monotherapy in patients with colorectal cancer who have failed one or two prior chemotherapeutic regimens
-
20127139 10.1007/s10637-010-9392-8 1:CAS:528:DC%2BC3MXhtVOrtL%2FN
-
Bennouna J, Lang I, Valladares-Ayerbes M, Boer K, Adenis A, Escudero P, Kim TY, Pover GM, Morris CD, Douillard JY (2011) A Phase II, open-label, randomised study to assess the efficacy and safety of the MEK1/2 inhibitor AZD6244 (ARRY-142886) versus capecitabine monotherapy in patients with colorectal cancer who have failed one or two prior chemotherapeutic regimens. Invest New Drugs 29:1021-1028
-
(2011)
Invest New Drugs
, vol.29
, pp. 1021-1028
-
-
Bennouna, J.1
Lang, I.2
Valladares-Ayerbes, M.3
Boer, K.4
Adenis, A.5
Escudero, P.6
Kim, T.Y.7
Pover, G.M.8
Morris, C.D.9
Douillard, J.Y.10
-
28
-
-
84864346162
-
A phase II open-label randomized study to assess the efficacy and safety of selumetinib (AZD6244 [ARRY-142886]) versus capecitabine in patients with advanced or metastatic pancreatic cancer who have failed first-line gemcitabine therapy
-
21594619 10.1007/s10637-011-9687-4 1:CAS:528:DC%2BC38XmvFalsb8%3D
-
Bodoky G, Timcheva C, Spigel DR, La Stella PJ, Ciuleanu TE, Pover G, Tebbutt NC (2012) A phase II open-label randomized study to assess the efficacy and safety of selumetinib (AZD6244 [ARRY-142886]) versus capecitabine in patients with advanced or metastatic pancreatic cancer who have failed first-line gemcitabine therapy. Invest New Drugs 30:1216-1223
-
(2012)
Invest New Drugs
, vol.30
, pp. 1216-1223
-
-
Bodoky, G.1
Timcheva, C.2
Spigel, D.R.3
La Stella, P.J.4
Ciuleanu, T.E.5
Pover, G.6
Tebbutt, N.C.7
-
29
-
-
79957917078
-
PI3K inhibition results in enhanced HER signaling and acquired ERK dependency in HER2-overexpressing breast cancer
-
21278786 10.1038/onc.2010.626 1:CAS:528:DC%2BC3MXht12msLs%3D
-
Serra V, Scaltriti M, Prudkin L, Eichhorn PJ, Ibrahim YH, Chandarlapaty S, Markman B, Rodriguez O, Guzman M, Rodriguez S, Gili M, Russillo M, Parra JL, Singh S, Arribas J, Rosen N, Baselga J (2011) PI3K inhibition results in enhanced HER signaling and acquired ERK dependency in HER2-overexpressing breast cancer. Oncogene 30:2547-2557
-
(2011)
Oncogene
, vol.30
, pp. 2547-2557
-
-
Serra, V.1
Scaltriti, M.2
Prudkin, L.3
Eichhorn, P.J.4
Ibrahim, Y.H.5
Chandarlapaty, S.6
Markman, B.7
Rodriguez, O.8
Guzman, M.9
Rodriguez, S.10
Gili, M.11
Russillo, M.12
Parra, J.L.13
Singh, S.14
Arribas, J.15
Rosen, N.16
Baselga, J.17
-
30
-
-
55949097252
-
Genetic predictors of MEK dependence in non-small cell lung cancer
-
19010912 10.1158/0008-5472.CAN-08-2223 1:CAS:528:DC%2BD1cXhtlOmt7vL
-
Pratilas CA, Hanrahan AJ, Halilovic E, Persaud Y, Soh J, Chitale D, Shigematsu H, Yamamoto H, Sawai A, Janakiraman M, Taylor BS, Pao W, Toyooka S, Ladanyi M, Gazdar A, Rosen N, Solit DB (2008) Genetic predictors of MEK dependence in non-small cell lung cancer. Cancer Res 68:9375-9383
-
(2008)
Cancer Res
, vol.68
, pp. 9375-9383
-
-
Pratilas, C.A.1
Hanrahan, A.J.2
Halilovic, E.3
Persaud, Y.4
Soh, J.5
Chitale, D.6
Shigematsu, H.7
Yamamoto, H.8
Sawai, A.9
Janakiraman, M.10
Taylor, B.S.11
Pao, W.12
Toyooka, S.13
Ladanyi, M.14
Gazdar, A.15
Rosen, N.16
Solit, D.B.17
-
31
-
-
84863596086
-
MEK inhibition leads to PI3K/AKT activation by relieving a negative feedback on ERBB receptors
-
22552284 10.1158/0008-5472.CAN-11-3747 1:CAS:528:DC%2BC38XpsFKktbk%3D
-
Turke AB, Song Y, Costa C, Cook R, Arteaga CL, Asara JM, Engelman JA (2012) MEK inhibition leads to PI3K/AKT activation by relieving a negative feedback on ERBB receptors. Cancer Res 72:3228-3237
-
(2012)
Cancer Res
, vol.72
, pp. 3228-3237
-
-
Turke, A.B.1
Song, Y.2
Costa, C.3
Cook, R.4
Arteaga, C.L.5
Asara, J.M.6
Engelman, J.A.7
-
32
-
-
37249013214
-
-
National Institutes of Health (NIH) Accessed 11 Apr 2012
-
National Institutes of Health (NIH) (2012) ClinicalTrials.gov. http://clinicaltrials.gov. Accessed 11 Apr 2012
-
(2012)
ClinicalTrials.gov
-
-
-
33
-
-
77953500567
-
Differences underlying EGFR and HER2 oncogene addiction
-
20160489 10.4161/cc.9.5.11096 1:CAS:528:DC%2BC3cXht12ktb7M
-
Faber AC, Wong KK, Engelman JA (2010) Differences underlying EGFR and HER2 oncogene addiction. Cell Cycle 9:851-852
-
(2010)
Cell Cycle
, vol.9
, pp. 851-852
-
-
Faber, A.C.1
Wong, K.K.2
Engelman, J.A.3
-
34
-
-
79960052850
-
Ras in cancer and developmental diseases
-
21779504 10.1177/1947601911411084 1:CAS:528:DC%2BC3MXpvFWlsbs%3D
-
Fernandez-Medarde A, Santos E (2011) Ras in cancer and developmental diseases. Genes Cancer 2:344-358
-
(2011)
Genes Cancer
, vol.2
, pp. 344-358
-
-
Fernandez-Medarde, A.1
Santos, E.2
-
35
-
-
57349194139
-
Effective use of PI3K and MEK inhibitors to treat mutant Kras G12D and PIK3CA H1047R murine lung cancers
-
19029981 10.1038/nm.1890 1:CAS:528:DC%2BD1cXhsVWhu7rI
-
Engelman JA, Chen L, Tan X, Crosby K, Guimaraes AR, Upadhyay R, Maira M, McNamara K, Perera SA, Song Y, Chirieac LR, Kaur R, Lightbown A, Simendinger J, Li T, Padera RF, Garcia-Echeverria C, Weissleder R, Mahmood U, Cantley LC, Wong KK (2008) Effective use of PI3K and MEK inhibitors to treat mutant Kras G12D and PIK3CA H1047R murine lung cancers. Nat Med 14:1351-1356
-
(2008)
Nat Med
, vol.14
, pp. 1351-1356
-
-
Engelman, J.A.1
Chen, L.2
Tan, X.3
Crosby, K.4
Guimaraes, A.R.5
Upadhyay, R.6
Maira, M.7
McNamara, K.8
Perera, S.A.9
Song, Y.10
Chirieac, L.R.11
Kaur, R.12
Lightbown, A.13
Simendinger, J.14
Li, T.15
Padera, R.F.16
Garcia-Echeverria, C.17
Weissleder, R.18
Mahmood, U.19
Cantley, L.C.20
Wong, K.K.21
more..
-
36
-
-
84856826293
-
Identification and characterization of NVP-BKM120, an orally available pan-class i PI3-Kinase inhibitor
-
22188813 10.1158/1535-7163.MCT-11-0474 1:CAS:528:DC%2BC38XitFWltb8%3D
-
Maira SM, Pecchi S, Huang A, Burger M, Knapp M, Sterker D, Schnell C, Guthy D, Nagel T, Wiesmann M, Brachmann S, Fritsch C, Dorsch M, Chene P, Shoemaker K, De Pover A, Menezes D, Martiny-Baron G, Fabbro D, Wilson CJ, Schlegel R, Hofmann F, Garcia-Echeverria C, Sellers WR, Voliva CF (2012) Identification and characterization of NVP-BKM120, an orally available pan-class I PI3-Kinase inhibitor. Mol Cancer Ther 11:317-328
-
(2012)
Mol Cancer Ther
, vol.11
, pp. 317-328
-
-
Maira, S.M.1
Pecchi, S.2
Huang, A.3
Burger, M.4
Knapp, M.5
Sterker, D.6
Schnell, C.7
Guthy, D.8
Nagel, T.9
Wiesmann, M.10
Brachmann, S.11
Fritsch, C.12
Dorsch, M.13
Chene, P.14
Shoemaker, K.15
De Pover, A.16
Menezes, D.17
Martiny-Baron, G.18
Fabbro, D.19
Wilson, C.J.20
Schlegel, R.21
Hofmann, F.22
Garcia-Echeverria, C.23
Sellers, W.R.24
Voliva, C.F.25
more..
-
37
-
-
84865620351
-
K-RAS mutant pancreatic tumors show higher sensitivity to MEK than to PI3K inhibition in vivo
-
22952903 10.1371/journal.pone.0044146 1:CAS:528:DC%2BC38XhtlSjs7rJ
-
Hofmann I, Weiss A, Elain G, Schwaederle M, Sterker D, Romanet V, Schmelzle T, Lai A, Brachmann SM, Bentires-Alj M, Roberts TM, Sellers WR, Hofmann F, Maira SM (2012) K-RAS mutant pancreatic tumors show higher sensitivity to MEK than to PI3K inhibition in vivo. PLoS ONE 7:e44146
-
(2012)
PLoS ONE
, vol.7
, pp. 44146
-
-
Hofmann, I.1
Weiss, A.2
Elain, G.3
Schwaederle, M.4
Sterker, D.5
Romanet, V.6
Schmelzle, T.7
Lai, A.8
Brachmann, S.M.9
Bentires-Alj, M.10
Roberts, T.M.11
Sellers, W.R.12
Hofmann, F.13
Maira, S.M.14
-
38
-
-
58249120506
-
Mutations in the phosphatidylinositol-3-kinase pathway predict for antitumor activity of the inhibitor PX-866 whereas oncogenic Ras is a dominant predictor for resistance
-
19117997 10.1158/0008-5472.CAN-07-6656 1:CAS:528:DC%2BD1MXmvFer
-
Ihle NT, Lemos R Jr, Wipf P, Yacoub A, Mitchell C, Siwak D, Mills GB, Dent P, Kirkpatrick DL, Powis G (2009) Mutations in the phosphatidylinositol-3- kinase pathway predict for antitumor activity of the inhibitor PX-866 whereas oncogenic Ras is a dominant predictor for resistance. Cancer Res 69:143-150
-
(2009)
Cancer Res
, vol.69
, pp. 143-150
-
-
Ihle, N.T.1
Lemos, Jr.R.2
Wipf, P.3
Yacoub, A.4
Mitchell, C.5
Siwak, D.6
Mills, G.B.7
Dent, P.8
Kirkpatrick, D.L.9
Powis, G.10
-
39
-
-
84859412054
-
Comprehensive predictive biomarker analysis for MEK inhibitor GSK1120212
-
22169769 10.1158/1535-7163.MCT-11-0505 1:CAS:528:DC%2BC38XjtlKisLw%3D
-
Jing J, Greshock J, Holbrook JD, Gilmartin A, Zhang X, McNeil E (2012) Comprehensive predictive biomarker analysis for MEK inhibitor GSK1120212. Mol Cancer Ther 11:720-729
-
(2012)
Mol Cancer Ther
, vol.11
, pp. 720-729
-
-
Jing, J.1
Greshock, J.2
Holbrook, J.D.3
Gilmartin, A.4
Zhang, X.5
McNeil, E.6
-
40
-
-
66249116702
-
PI3K pathway activation mediates resistance to MEK inhibitors in KRAS mutant cancers
-
19401449 10.1158/0008-5472.CAN-08-4765 1:CAS:528:DC%2BD1MXlvFWltLg%3D
-
Wee S, Jagani Z, Xiang KX, Loo A, Dorsch M, Yao YM, Sellers WR, Lengauer C (2009) PI3K pathway activation mediates resistance to MEK inhibitors in KRAS mutant cancers. Cancer Res 69:4286-4293
-
(2009)
Cancer Res
, vol.69
, pp. 4286-4293
-
-
Wee, S.1
Jagani, Z.2
Xiang, K.X.3
Loo, A.4
Dorsch, M.5
Yao, Y.M.6
Sellers, W.R.7
Lengauer, C.8
-
41
-
-
77951658161
-
KRAS mutant lung cancer cells are differentially responsive to MEK inhibitor due to AKT or STAT3 activation: Implication for combinatorial approach
-
20358631 10.1002/mc.20607 1:CAS:528:DC%2BC3cXktVCls7o%3D
-
Yoon YK, Kim HP, Han SW, Oh DY, Im SA, Bang YJ, Kim TY (2010) KRAS mutant lung cancer cells are differentially responsive to MEK inhibitor due to AKT or STAT3 activation: implication for combinatorial approach. Mol Carcinog 49:353-362
-
(2010)
Mol Carcinog
, vol.49
, pp. 353-362
-
-
Yoon, Y.K.1
Kim, H.P.2
Han, S.W.3
Oh, D.Y.4
Im, S.A.5
Bang, Y.J.6
Kim, T.Y.7
-
42
-
-
77950261074
-
Transcriptional pathway signatures predict MEK addiction and response to selumetinib (AZD6244)
-
20215513 10.1158/0008-5472.CAN-09-1577 1:CAS:528:DC%2BC3cXjtFygt7o%3D
-
Dry JR, Pavey S, Pratilas CA, Harbron C, Runswick S, Hodgson D, Chresta C, McCormack R, Byrne N, Cockerill M, Graham A, Beran G, Cassidy A, Haggerty C, Brown H, Ellison G, Dering J, Taylor BS, Stark M, Bonazzi V, Ravishankar S, Packer L, Xing F, Solit DB, Finn RS, Rosen N, Hayward NK, French T, Smith PD (2010) Transcriptional pathway signatures predict MEK addiction and response to selumetinib (AZD6244). Cancer Res 70:2264-2273
-
(2010)
Cancer Res
, vol.70
, pp. 2264-2273
-
-
Dry, J.R.1
Pavey, S.2
Pratilas, C.A.3
Harbron, C.4
Runswick, S.5
Hodgson, D.6
Chresta, C.7
McCormack, R.8
Byrne, N.9
Cockerill, M.10
Graham, A.11
Beran, G.12
Cassidy, A.13
Haggerty, C.14
Brown, H.15
Ellison, G.16
Dering, J.17
Taylor, B.S.18
Stark, M.19
Bonazzi, V.20
Ravishankar, S.21
Packer, L.22
Xing, F.23
Solit, D.B.24
Finn, R.S.25
Rosen, N.26
Hayward, N.K.27
French, T.28
Smith, P.D.29
more..
-
43
-
-
77956030786
-
Inhibition of mutated, activated BRAF in metastatic melanoma
-
20818844 10.1056/NEJMoa1002011 1:CAS:528:DC%2BC3cXhtVyksb3M
-
Flaherty KT, Puzanov I, Kim KB, Ribas A, McArthur GA, Sosman JA, O'Dwyer PJ, Lee RJ, Grippo JF, Nolop K, Chapman PB (2010) Inhibition of mutated, activated BRAF in metastatic melanoma. N Engl J Med 363:809-819
-
(2010)
N Engl J Med
, vol.363
, pp. 809-819
-
-
Flaherty, K.T.1
Puzanov, I.2
Kim, K.B.3
Ribas, A.4
McArthur, G.A.5
Sosman, J.A.6
O'Dwyer, P.J.7
Lee, R.J.8
Grippo, J.F.9
Nolop, K.10
Chapman, P.B.11
-
44
-
-
18444374405
-
Mutations of the BRAF gene in human cancer
-
12068308 10.1038/nature00766 1:CAS:528:DC%2BD38XkvVagsLo%3D
-
Davies H, Bignell GR, Cox C, Stephens P, Edkins S, Clegg S, Teague J, Woffendin H, Garnett MJ, Bottomley W, Davis N, Dicks E, Ewing R, Floyd Y, Gray K, Hall S, Hawes R, Hughes J, Kosmidou V, Menzies A, Mould C, Parker A, Stevens C, Watt S, Hooper S, Wilson R, Jayatilake H, Gusterson BA, Cooper C, Shipley J, Hargrave D, Pritchard-Jones K, Maitland N, Chenevix-Trench G, Riggins GJ, Bigner DD, Palmieri G, Cossu A, Flanagan A, Nicholson A, Ho JW, Leung SY, Yuen ST, Weber BL, Seigler HF, Darrow TL, Paterson H, Marais R, Marshall CJ, Wooster R, Stratton MR, Futreal PA (2002) Mutations of the BRAF gene in human cancer. Nature 417:949-954
-
(2002)
Nature
, vol.417
, pp. 949-954
-
-
Davies, H.1
Bignell, G.R.2
Cox, C.3
Stephens, P.4
Edkins, S.5
Clegg, S.6
Teague, J.7
Woffendin, H.8
Garnett, M.J.9
Bottomley, W.10
Davis, N.11
Dicks, E.12
Ewing, R.13
Floyd, Y.14
Gray, K.15
Hall, S.16
Hawes, R.17
Hughes, J.18
Kosmidou, V.19
Menzies, A.20
Mould, C.21
Parker, A.22
Stevens, C.23
Watt, S.24
Hooper, S.25
Wilson, R.26
Jayatilake, H.27
Gusterson, B.A.28
Cooper, C.29
Shipley, J.30
Hargrave, D.31
Pritchard-Jones, K.32
Maitland, N.33
Chenevix-Trench, G.34
Riggins, G.J.35
Bigner, D.D.36
Palmieri, G.37
Cossu, A.38
Flanagan, A.39
Nicholson, A.40
Ho, J.W.41
Leung, S.Y.42
Yuen, S.T.43
Weber, B.L.44
Seigler, H.F.45
Darrow, T.L.46
Paterson, H.47
Marais, R.48
Marshall, C.J.49
Wooster, R.50
Stratton, M.R.51
Futreal, P.A.52
more..
-
45
-
-
80053307869
-
Potential therapeutic strategies to overcome acquired resistance to BRAF or MEK inhibitors in BRAF mutant cancers
-
21505228
-
Corcoran RB, Settleman J, Engelman JA (2011) Potential therapeutic strategies to overcome acquired resistance to BRAF or MEK inhibitors in BRAF mutant cancers. Oncotarget 2:336-346
-
(2011)
Oncotarget
, vol.2
, pp. 336-346
-
-
Corcoran, R.B.1
Settleman, J.2
Engelman, J.A.3
-
46
-
-
78649436372
-
BRAF gene amplification can promote acquired resistance to MEK inhibitors in cancer cells harboring the BRAF V600E mutation
-
21098728 10.1126/scisignal.2001148 1:CAS:528:DC%2BC3MXhs1SqtL4%3D
-
Corcoran RB, Dias-Santagata D, Bergethon K, Iafrate AJ, Settleman J, Engelman JA (2010) BRAF gene amplification can promote acquired resistance to MEK inhibitors in cancer cells harboring the BRAF V600E mutation. Sci Signal 3:ra84
-
(2010)
Sci Signal
, vol.3
, pp. 84
-
-
Corcoran, R.B.1
Dias-Santagata, D.2
Bergethon, K.3
Iafrate, A.J.4
Settleman, J.5
Engelman, J.A.6
-
47
-
-
83455254767
-
RAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAF(V600E)
-
22113612 10.1038/nature10662 1:CAS:528:DC%2BC3MXhsFWqtL%2FN
-
Poulikakos PI, Persaud Y, Janakiraman M, Kong X, Ng C, Moriceau G, Shi H, Atefi M, Titz B, Gabay MT, Salton M, Dahlman KB, Tadi M, Wargo JA, Flaherty KT, Kelley MC, Misteli T, Chapman PB, Sosman JA, Graeber TG, Ribas A, Lo RS, Rosen N, Solit DB (2011) RAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAF(V600E). Nature 480:387-390
-
(2011)
Nature
, vol.480
, pp. 387-390
-
-
Poulikakos, P.I.1
Persaud, Y.2
Janakiraman, M.3
Kong, X.4
Ng, C.5
Moriceau, G.6
Shi, H.7
Atefi, M.8
Titz, B.9
Gabay, M.T.10
Salton, M.11
Dahlman, K.B.12
Tadi, M.13
Wargo, J.A.14
Flaherty, K.T.15
Kelley, M.C.16
Misteli, T.17
Chapman, P.B.18
Sosman, J.A.19
Graeber, T.G.20
Ribas, A.21
Lo, R.S.22
Rosen, N.23
Solit, D.B.24
more..
-
48
-
-
49649118852
-
Elevated CRAF as a potential mechanism of acquired resistance to BRAF inhibition in melanoma
-
18559533 10.1158/0008-5472.CAN-07-6787 1:CAS:528:DC%2BD1cXnt1ejsbs%3D
-
Montagut C, Sharma SV, Shioda T, McDermott U, Ulman M, Ulkus LE, Dias-Santagata D, Stubbs H, Lee DY, Singh A, Drew L, Haber DA, Settleman J (2008) Elevated CRAF as a potential mechanism of acquired resistance to BRAF inhibition in melanoma. Cancer Res 68:4853-4861
-
(2008)
Cancer Res
, vol.68
, pp. 4853-4861
-
-
Montagut, C.1
Sharma, S.V.2
Shioda, T.3
McDermott, U.4
Ulman, M.5
Ulkus, L.E.6
Dias-Santagata, D.7
Stubbs, H.8
Lee, D.Y.9
Singh, A.10
Drew, L.11
Haber, D.A.12
Settleman, J.13
-
49
-
-
78650309875
-
COT drives resistance to RAF inhibition through MAP kinase pathway reactivation
-
21107320 10.1038/nature09627 1:CAS:528:DC%2BC3cXhsVOrsLvP
-
Johannessen CM, Boehm JS, Kim SY, Thomas SR, Wardwell L, Johnson LA, Emery CM, Stransky N, Cogdill AP, Barretina J, Caponigro G, Hieronymus H, Murray RR, Salehi-Ashtiani K, Hill DE, Vidal M, Zhao JJ, Yang X, Alkan O, Kim S, Harris JL, Wilson CJ, Myer VE, Finan PM, Root DE, Roberts TM, Golub T, Flaherty KT, Dummer R, Weber BL, Sellers WR, Schlegel R, Wargo JA, Hahn WC, Garraway LA (2010) COT drives resistance to RAF inhibition through MAP kinase pathway reactivation. Nature 468:968-972
-
(2010)
Nature
, vol.468
, pp. 968-972
-
-
Johannessen, C.M.1
Boehm, J.S.2
Kim, S.Y.3
Thomas, S.R.4
Wardwell, L.5
Johnson, L.A.6
Emery, C.M.7
Stransky, N.8
Cogdill, A.P.9
Barretina, J.10
Caponigro, G.11
Hieronymus, H.12
Murray, R.R.13
Salehi-Ashtiani, K.14
Hill, D.E.15
Vidal, M.16
Zhao, J.J.17
Yang, X.18
Alkan, O.19
Kim, S.20
Harris, J.L.21
Wilson, C.J.22
Myer, V.E.23
Finan, P.M.24
Root, D.E.25
Roberts, T.M.26
Golub, T.27
Flaherty, K.T.28
Dummer, R.29
Weber, B.L.30
Sellers, W.R.31
Schlegel, R.32
Wargo, J.A.33
Hahn, W.C.34
Garraway, L.A.35
more..
-
50
-
-
84862305656
-
Acquired resistance to BRAF inhibition can confer cross-resistance to combined BRAF/MEK inhibition
-
22437314 10.1038/jid.2012.63 1:CAS:528:DC%2BC38Xjslemt7w%3D
-
Gowrishankar K, Snoyman S, Pupo GM, Becker TM, Kefford RF, Rizos H (2012) Acquired resistance to BRAF inhibition can confer cross-resistance to combined BRAF/MEK inhibition. J Invest Dermatol 132:1850-1859
-
(2012)
J Invest Dermatol
, vol.132
, pp. 1850-1859
-
-
Gowrishankar, K.1
Snoyman, S.2
Pupo, G.M.3
Becker, T.M.4
Kefford, R.F.5
Rizos, H.6
-
51
-
-
78650303507
-
Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation
-
21107323 10.1038/nature09626 1:CAS:528:DC%2BC3cXhsVOrsbjI
-
Nazarian R, Shi H, Wang Q, Kong X, Koya RC, Lee H, Chen Z, Lee MK, Attar N, Sazegar H, Chodon T, Nelson SF, McArthur G, Sosman JA, Ribas A, Lo RS (2010) Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation. Nature 468:973-977
-
(2010)
Nature
, vol.468
, pp. 973-977
-
-
Nazarian, R.1
Shi, H.2
Wang, Q.3
Kong, X.4
Koya, R.C.5
Lee, H.6
Chen, Z.7
Lee, M.K.8
Attar, N.9
Sazegar, H.10
Chodon, T.11
Nelson, S.F.12
McArthur, G.13
Sosman, J.A.14
Ribas, A.15
Lo, R.S.16
-
52
-
-
80051625929
-
Dissecting therapeutic resistance to RAF inhibition in melanoma by tumor genomic profiling
-
21383288 10.1200/JCO.2010.33.2312 1:CAS:528:DC%2BC3MXhtFCqtLfO
-
Wagle N, Emery C, Berger MF, Davis MJ, Sawyer A, Pochanard P, Kehoe SM, Johannessen CM, Macconaill LE, Hahn WC, Meyerson M, Garraway LA (2011) Dissecting therapeutic resistance to RAF inhibition in melanoma by tumor genomic profiling. J Clin Oncol 29:3085-3096
-
(2011)
J Clin Oncol
, vol.29
, pp. 3085-3096
-
-
Wagle, N.1
Emery, C.2
Berger, M.F.3
Davis, M.J.4
Sawyer, A.5
Pochanard, P.6
Kehoe, S.M.7
Johannessen, C.M.8
MacConaill, L.E.9
Hahn, W.C.10
Meyerson, M.11
Garraway, L.A.12
-
53
-
-
84864277515
-
Efficacy and safety of oral MEK162 in patients with locally advanced and unresectable or metastatic cutaneous melanoma harboring BRAFV600 or NRAS mutations
-
abstr 8511
-
Ascierto PA, Berking C, Agarwala SS, Schadendorf D, Van Herpen C, Queirolo P, Blank CU, Hauschild A, Beck JT, Zubel A, Niazi F, Wandel S, Dummer R (2012) Efficacy and safety of oral MEK162 in patients with locally advanced and unresectable or metastatic cutaneous melanoma harboring BRAFV600 or NRAS mutations. J Clin Oncol 30 (suppl; abstr 8511)
-
(2012)
J Clin Oncol
, vol.30
, Issue.SUPPL.
-
-
Ascierto, P.A.1
Berking, C.2
Agarwala, S.S.3
Schadendorf, D.4
Van Herpen, C.5
Queirolo, P.6
Blank, C.U.7
Hauschild, A.8
Beck, J.T.9
Zubel, A.10
Niazi, F.11
Wandel, S.12
Dummer, R.13
-
54
-
-
84864371119
-
Activity of the oral MEK inhibitor trametinib in patients with advanced melanoma: A phase 1 dose-escalation trial
-
22805292 10.1016/S1470-2045(12)70269-3 1:CAS:528:DC%2BC38XhtFajsLjF
-
Falchook GS, Lewis KD, Infante JR, Gordon MS, Vogelzang NJ, De Marini DJ, Sun P, Moy C, Szabo SA, Roadcap LT, Peddareddigari VG, Lebowitz PF, Le NT, Burris HA 3rd, Messersmith WA, O'Dwyer PJ, Kim KB, Flaherty K, Bendell JC, Gonzalez R, Kurzrock R, Fecher LA (2012) Activity of the oral MEK inhibitor trametinib in patients with advanced melanoma: a phase 1 dose-escalation trial. Lancet Oncol 13:782-789
-
(2012)
Lancet Oncol
, vol.13
, pp. 782-789
-
-
Falchook, G.S.1
Lewis, K.D.2
Infante, J.R.3
Gordon, M.S.4
Vogelzang, N.J.5
De Marini, D.J.6
Sun, P.7
Moy, C.8
Szabo, S.A.9
Roadcap, L.T.10
Peddareddigari, V.G.11
Lebowitz, P.F.12
Le, N.T.13
Burris, H.A.14
Messersmith, W.A.15
O'Dwyer, P.J.16
Kim, K.B.17
Flaherty, K.18
Bendell, J.C.19
Gonzalez, R.20
Kurzrock, R.21
Fecher, L.A.22
more..
-
55
-
-
84862732834
-
Combinations of BRAF, MEK, and PI3K/mTOR inhibitors overcome acquired resistance to the BRAF inhibitor GSK2118436 dabrafenib, mediated by NRAS or MEK mutations
-
22389471 10.1158/1535-7163.MCT-11-0989 1:CAS:528:DC%2BC38Xltl2ntbY%3D
-
Greger JG, Eastman SD, Zhang V, Bleam MR, Hughes AM, Smitheman KN, Dickerson SH, Laquerre SG, Liu L, Gilmer TM (2012) Combinations of BRAF, MEK, and PI3K/mTOR inhibitors overcome acquired resistance to the BRAF inhibitor GSK2118436 dabrafenib, mediated by NRAS or MEK mutations. Mol Cancer Ther 11:909-920
-
(2012)
Mol Cancer Ther
, vol.11
, pp. 909-920
-
-
Greger, J.G.1
Eastman, S.D.2
Zhang, V.3
Bleam, M.R.4
Hughes, A.M.5
Smitheman, K.N.6
Dickerson, S.H.7
Laquerre, S.G.8
Liu, L.9
Gilmer, T.M.10
-
56
-
-
84862908526
-
RAS mutations are associated with the development of cutaneous squamous cell tumors in patients treated with RAF inhibitors
-
22067401 10.1200/JCO.2011.36.7680 1:CAS:528:DC%2BC38XjsFCitL4%3D
-
Oberholzer PA, Kee D, Dziunycz P, Sucker A, Kamsukom N, Jones R, Roden C, Chalk CJ, Ardlie K, Palescandolo E, Piris A, MacConaill LE, Robert C, Hofbauer GF, McArthur GA, Schadendorf D, Garraway LA (2012) RAS mutations are associated with the development of cutaneous squamous cell tumors in patients treated with RAF inhibitors. J Clin Oncol 30:316-321
-
(2012)
J Clin Oncol
, vol.30
, pp. 316-321
-
-
Oberholzer, P.A.1
Kee, D.2
Dziunycz, P.3
Sucker, A.4
Kamsukom, N.5
Jones, R.6
Roden, C.7
Chalk, C.J.8
Ardlie, K.9
Palescandolo, E.10
Piris, A.11
MacConaill, L.E.12
Robert, C.13
Hofbauer, G.F.14
McArthur, G.A.15
Schadendorf, D.16
Garraway, L.A.17
-
57
-
-
84862908097
-
RAS mutations in cutaneous squamous-cell carcinomas in patients treated with BRAF inhibitors
-
22256804 10.1056/NEJMoa1105358 1:CAS:528:DC%2BC38Xht1yltr8%3D
-
Su F, Viros A, Milagre C, Trunzer K, Bollag G, Spleiss O, Reis-Filho JS, Kong X, Koya RC, Flaherty KT, Chapman PB, Kim MJ, Hayward R, Martin M, Yang H, Wang Q, Hilton H, Hang JS, Noe J, Lambros M, Geyer F, Dhomen N, Niculescu-Duvaz I, Zambon A, Niculescu-Duvaz D, Preece N, Robert L, Otte NJ, Mok S, Kee D, Ma Y, Zhang C, Habets G, Burton EA, Wong B, Nguyen H, Kockx M, Andries L, Lestini B, Nolop KB, Lee RJ, Joe AK, Troy JL, Gonzalez R, Hutson TE, Puzanov I, Chmielowski B, Springer CJ, McArthur GA, Sosman JA, Lo RS, Ribas A, Marais R (2012) RAS mutations in cutaneous squamous-cell carcinomas in patients treated with BRAF inhibitors. N Engl J Med 366:207-215
-
(2012)
N Engl J Med
, vol.366
, pp. 207-215
-
-
Su, F.1
Viros, A.2
Milagre, C.3
Trunzer, K.4
Bollag, G.5
Spleiss, O.6
Reis-Filho, J.S.7
Kong, X.8
Koya, R.C.9
Flaherty, K.T.10
Chapman, P.B.11
Kim, M.J.12
Hayward, R.13
Martin, M.14
Yang, H.15
Wang, Q.16
Hilton, H.17
Hang, J.S.18
Noe, J.19
Lambros, M.20
Geyer, F.21
Dhomen, N.22
Niculescu-Duvaz, I.23
Zambon, A.24
Niculescu-Duvaz, D.25
Preece, N.26
Robert, L.27
Otte, N.J.28
Mok, S.29
Kee, D.30
Ma, Y.31
Zhang, C.32
Habets, G.33
Burton, E.A.34
Wong, B.35
Nguyen, H.36
Kockx, M.37
Andries, L.38
Lestini, B.39
Nolop, K.B.40
Lee, R.J.41
Joe, A.K.42
Troy, J.L.43
Gonzalez, R.44
Hutson, T.E.45
Puzanov, I.46
Chmielowski, B.47
Springer, C.J.48
McArthur, G.A.49
Sosman, J.A.50
Lo, R.S.51
Ribas, A.52
Marais, R.53
more..
-
58
-
-
84868224906
-
Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations
-
23020132 10.1056/NEJMoa1210093 1:CAS:528:DC%2BC38Xhs1eksLrJ
-
Flaherty KT, Infante JR, Daud A, Gonzalez R, Kefford RF, Sosman J, Hamid O, Schuchter L, Cebon J, Ibrahim N, Kudchadkar R, Burris HA 3rd, Falchook G, Algazi A, Lewis K, Long GV, Puzanov I, Lebowitz P, Singh A, Little S, Sun P, Allred A, Ouellet D, Kim KB, Patel K, Weber J (2012) Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations. N Engl J Med 367:1694-1703
-
(2012)
N Engl J Med
, vol.367
, pp. 1694-1703
-
-
Flaherty, K.T.1
Infante, J.R.2
Daud, A.3
Gonzalez, R.4
Kefford, R.F.5
Sosman, J.6
Hamid, O.7
Schuchter, L.8
Cebon, J.9
Ibrahim, N.10
Kudchadkar, R.11
Burris, H.A.12
Falchook, G.13
Algazi, A.14
Lewis, K.15
Long, G.V.16
Puzanov, I.17
Lebowitz, P.18
Singh, A.19
Little, S.20
Sun, P.21
Allred, A.22
Ouellet, D.23
Kim, K.B.24
Patel, K.25
Weber, J.26
more..
-
59
-
-
83355170673
-
Reversing melanoma cross-resistance to BRAF and MEK inhibitors by co-targeting the AKT/mTOR pathway
-
22194965 10.1371/journal.pone.0028973 1:CAS:528:DC%2BC38XhsFentQ%3D%3D
-
Atefi M, von Euw E, Attar N, Ng C, Chu C, Guo D, Nazarian R, Chmielowski B, Glaspy JA, Comin-Anduix B, Mischel PS, Lo RS, Ribas A (2011) Reversing melanoma cross-resistance to BRAF and MEK inhibitors by co-targeting the AKT/mTOR pathway. PLoS ONE 6:e28973
-
(2011)
PLoS ONE
, vol.6
, pp. 28973
-
-
Atefi, M.1
Von Euw, E.2
Attar, N.3
Ng, C.4
Chu, C.5
Guo, D.6
Nazarian, R.7
Chmielowski, B.8
Glaspy, J.A.9
Comin-Anduix, B.10
Mischel, P.S.11
Lo, R.S.12
Ribas, A.13
-
60
-
-
79960946383
-
Combinatorial treatments that overcome PDGFRbeta-driven resistance of melanoma cells to V600EB-RAF inhibition
-
21803746 10.1158/0008-5472.CAN-11-0140 1:CAS:528:DC%2BC3MXpsVOht7o%3D
-
Shi H, Kong X, Ribas A, Lo RS (2011) Combinatorial treatments that overcome PDGFRbeta-driven resistance of melanoma cells to V600EB-RAF inhibition. Cancer Res 71:5067-5074
-
(2011)
Cancer Res
, vol.71
, pp. 5067-5074
-
-
Shi, H.1
Kong, X.2
Ribas, A.3
Lo, R.S.4
-
61
-
-
78650008177
-
Acquired resistance to BRAF inhibitors mediated by a RAF kinase switch in melanoma can be overcome by cotargeting MEK and IGF-1R/PI3K
-
21156289 10.1016/j.ccr.2010.11.023 1:CAS:528:DC%2BC3cXhsFGhsbjJ
-
Villanueva J, Vultur A, Lee JT, Somasundaram R, Fukunaga-Kalabis M, Cipolla AK, Wubbenhorst B, Xu X, Gimotty PA, Kee D, Santiago-Walker AE, Letrero R, D'Andrea K, Pushparajan A, Hayden JE, Brown KD, Laquerre S, McArthur GA, Sosman JA, Nathanson KL, Herlyn M (2010) Acquired resistance to BRAF inhibitors mediated by a RAF kinase switch in melanoma can be overcome by cotargeting MEK and IGF-1R/PI3K. Cancer Cell 18:683-695
-
(2010)
Cancer Cell
, vol.18
, pp. 683-695
-
-
Villanueva, J.1
Vultur, A.2
Lee, J.T.3
Somasundaram, R.4
Fukunaga-Kalabis, M.5
Cipolla, A.K.6
Wubbenhorst, B.7
Xu, X.8
Gimotty, P.A.9
Kee, D.10
Santiago-Walker, A.E.11
Letrero, R.12
D'Andrea, K.13
Pushparajan, A.14
Hayden, J.E.15
Brown, K.D.16
Laquerre, S.17
McArthur, G.A.18
Sosman, J.A.19
Nathanson, K.L.20
Herlyn, M.21
more..
-
62
-
-
0348223934
-
NRAS and BRAF mutations arise early during melanoma pathogenesis and are preserved throughout tumor progression
-
14695152 1:CAS:528:DC%2BD3sXhtVSqurjM
-
Omholt K, Platz A, Kanter L, Ringborg U, Hansson J (2003) NRAS and BRAF mutations arise early during melanoma pathogenesis and are preserved throughout tumor progression. Clin Cancer Res 9:6483-6488
-
(2003)
Clin Cancer Res
, vol.9
, pp. 6483-6488
-
-
Omholt, K.1
Platz, A.2
Kanter, L.3
Ringborg, U.4
Hansson, J.5
-
63
-
-
79251474400
-
Clinical correlates of NRAS and BRAF mutations in primary human melanoma
-
20975100 10.1158/1078-0432.CCR-10-2276 1:CAS:528:DC%2BC3MXmslyrsA%3D%3D
-
Ellerhorst JA, Greene VR, Ekmekcioglu S, Warneke CL, Johnson MM, Cooke CP, Wang LE, Prieto VG, Gershenwald JE, Wei Q, Grimm EA (2011) Clinical correlates of NRAS and BRAF mutations in primary human melanoma. Clin Cancer Res 17:229-235
-
(2011)
Clin Cancer Res
, vol.17
, pp. 229-235
-
-
Ellerhorst, J.A.1
Greene, V.R.2
Ekmekcioglu, S.3
Warneke, C.L.4
Johnson, M.M.5
Cooke, C.P.6
Wang, L.E.7
Prieto, V.G.8
Gershenwald, J.E.9
Wei, Q.10
Grimm, E.A.11
-
64
-
-
31144453233
-
BRAF mutation predicts sensitivity to MEK inhibition
-
16273091 10.1038/nature04304 1:CAS:528:DC%2BD28XkvF2mtw%3D%3D
-
Solit DB, Garraway LA, Pratilas CA, Sawai A, Getz G, Basso A, Ye Q, Lobo JM, She Y, Osman I, Golub TR, Sebolt-Leopold J, Sellers WR, Rosen N (2006) BRAF mutation predicts sensitivity to MEK inhibition. Nature 439:358-362
-
(2006)
Nature
, vol.439
, pp. 358-362
-
-
Solit, D.B.1
Garraway, L.A.2
Pratilas, C.A.3
Sawai, A.4
Getz, G.5
Basso, A.6
Ye, Q.7
Lobo, J.M.8
She, Y.9
Osman, I.10
Golub, T.R.11
Sebolt-Leopold, J.12
Sellers, W.R.13
Rosen, N.14
-
65
-
-
43749103335
-
Phase i pharmacokinetic and pharmacodynamic study of the oral, small-molecule mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244 (ARRY-142886) in patients with advanced cancers
-
18390968 10.1200/JCO.2007.14.4956 1:CAS:528:DC%2BD1cXms1OrtL8%3D
-
Adjei AA, Cohen RB, Franklin W, Morris C, Wilson D, Molina JR, Hanson LJ, Gore L, Chow L, Leong S, Maloney L, Gordon G, Simmons H, Marlow A, Litwiler K, Brown S, Poch G, Kane K, Haney J, Eckhardt SG (2008) Phase I pharmacokinetic and pharmacodynamic study of the oral, small-molecule mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244 (ARRY-142886) in patients with advanced cancers. J Clin Oncol 26:2139-2146
-
(2008)
J Clin Oncol
, vol.26
, pp. 2139-2146
-
-
Adjei, A.A.1
Cohen, R.B.2
Franklin, W.3
Morris, C.4
Wilson, D.5
Molina, J.R.6
Hanson, L.J.7
Gore, L.8
Chow, L.9
Leong, S.10
Maloney, L.11
Gordon, G.12
Simmons, H.13
Marlow, A.14
Litwiler, K.15
Brown, S.16
Poch, G.17
Kane, K.18
Haney, J.19
Eckhardt, S.G.20
more..
-
66
-
-
84856009717
-
Phase II, open-label, randomized trial of the MEK1/2 inhibitor selumetinib as monotherapy versus temozolomide in patients with advanced melanoma
-
22048237 10.1158/1078-0432.CCR-11-1491 1:CAS:528:DC%2BC38XhtVGqs70%3D
-
Kirkwood JM, Bastholt L, Robert C, Sosman J, Larkin J, Hersey P, Middleton M, Cantarini M, Zazulina V, Kemsley K, Dummer R (2012) Phase II, open-label, randomized trial of the MEK1/2 inhibitor selumetinib as monotherapy versus temozolomide in patients with advanced melanoma. Clin Cancer Res 18:555-567
-
(2012)
Clin Cancer Res
, vol.18
, pp. 555-567
-
-
Kirkwood, J.M.1
Bastholt, L.2
Robert, C.3
Sosman, J.4
Larkin, J.5
Hersey, P.6
Middleton, M.7
Cantarini, M.8
Zazulina, V.9
Kemsley, K.10
Dummer, R.11
-
67
-
-
84866930352
-
Combined PI3K/mTOR and MEK inhibition provides broad anti-tumor activity in faithful murine cancer models
-
22872574 10.1158/1078-0432.CCR-12-0563 1:CAS:528:DC%2BC38XhsFSgtbfI
-
Roberts PJ, Usary J, Darr D, Dillon PM, Pfefferle AD, Whittle MC, Duncan JS, Johnson SM, Combest A, Jin J, Zamboni WC, Johnson GL, Perou CM, Sharpless NE (2012) Combined PI3K/mTOR and MEK inhibition provides broad anti-tumor activity in faithful murine cancer models. Clin Cancer Res 18:5290-5303
-
(2012)
Clin Cancer Res
, vol.18
, pp. 5290-5303
-
-
Roberts, P.J.1
Usary, J.2
Darr, D.3
Dillon, P.M.4
Pfefferle, A.D.5
Whittle, M.C.6
Duncan, J.S.7
Johnson, S.M.8
Combest, A.9
Jin, J.10
Zamboni, W.C.11
Johnson, G.L.12
Perou, C.M.13
Sharpless, N.E.14
-
68
-
-
65349189958
-
American Society of Clinical Oncology provisional clinical opinion: Testing for KRAS gene mutations in patients with metastatic colorectal carcinoma to predict response to anti-epidermal growth factor receptor monoclonal antibody therapy
-
19188670 10.1200/JCO.2009.21.9170
-
Allegra CJ, Jessup JM, Somerfield MR, Hamilton SR, Hammond EH, Hayes DF, McAllister PK, Morton RF, Schilsky RL (2009) American Society of Clinical Oncology provisional clinical opinion: testing for KRAS gene mutations in patients with metastatic colorectal carcinoma to predict response to anti-epidermal growth factor receptor monoclonal antibody therapy. J Clin Oncol 27:2091-2096
-
(2009)
J Clin Oncol
, vol.27
, pp. 2091-2096
-
-
Allegra, C.J.1
Jessup, J.M.2
Somerfield, M.R.3
Hamilton, S.R.4
Hammond, E.H.5
Hayes, D.F.6
McAllister, P.K.7
Morton, R.F.8
Schilsky, R.L.9
-
69
-
-
79957523828
-
KRAS, BRAF, PIK3CA, and PTEN mutations: Implications for targeted therapies in metastatic colorectal cancer
-
21163703 10.1016/S1470-2045(10)70209-6
-
De Roock W, De Vriendt V, Normanno N, Ciardiello F, Tejpar S (2011) KRAS, BRAF, PIK3CA, and PTEN mutations: implications for targeted therapies in metastatic colorectal cancer. Lancet Oncol 12:594-603
-
(2011)
Lancet Oncol
, vol.12
, pp. 594-603
-
-
De Roock, W.1
De Vriendt, V.2
Normanno, N.3
Ciardiello, F.4
Tejpar, S.5
-
70
-
-
77955277111
-
Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: A retrospective consortium analysis
-
20619739 10.1016/S1470-2045(10)70130-3
-
De Roock W, Claes B, Bernasconi D, De Schutter J, Biesmans B, Fountzilas G, Kalogeras KT, Kotoula V, Papamichael D, Laurent-Puig P, Penault-Llorca F, Rougier P, Vincenzi B, Santini D, Tonini G, Cappuzzo F, Frattini M, Molinari F, Saletti P, De Dosso S, Martini M, Bardelli A, Siena S, Sartore-Bianchi A, Tabernero J, Macarulla T, Di Fiore F, Gangloff AO, Ciardiello F, Pfeiffer P, Qvortrup C, Hansen TP, Van Cutsem E, Piessevaux H, Lambrechts D, Delorenzi M, Tejpar S (2010) Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis. Lancet Oncol 11:753-762
-
(2010)
Lancet Oncol
, vol.11
, pp. 753-762
-
-
De Roock, W.1
Claes, B.2
Bernasconi, D.3
De Schutter, J.4
Biesmans, B.5
Fountzilas, G.6
Kalogeras, K.T.7
Kotoula, V.8
Papamichael, D.9
Laurent-Puig, P.10
Penault-Llorca, F.11
Rougier, P.12
Vincenzi, B.13
Santini, D.14
Tonini, G.15
Cappuzzo, F.16
Frattini, M.17
Molinari, F.18
Saletti, P.19
De Dosso, S.20
Martini, M.21
Bardelli, A.22
Siena, S.23
Sartore-Bianchi, A.24
Tabernero, J.25
MacArulla, T.26
Di Fiore, F.27
Gangloff, A.O.28
Ciardiello, F.29
Pfeiffer, P.30
Qvortrup, C.31
Hansen, T.P.32
Van Cutsem, E.33
Piessevaux, H.34
Lambrechts, D.35
Delorenzi, M.36
Tejpar, S.37
more..
-
71
-
-
84862999938
-
Emergence of KRAS mutations and acquired resistance to anti-EGFR therapy in colorectal cancer
-
22722830 1:CAS:528:DC%2BC38XpsVSrsb4%3D
-
Misale S, Yaeger R, Hobor S, Scala E, Janakiraman M, Liska D, Valtorta E, Schiavo R, Buscarino M, Siravegna G, Bencardino K, Cercek A, Chen CT, Veronese S, Zanon C, Sartore-Bianchi A, Gambacorta M, Gallicchio M, Vakiani E, Boscaro V, Medico E, Weiser M, Siena S, Di Nicolantonio F, Solit D, Bardelli A (2012) Emergence of KRAS mutations and acquired resistance to anti-EGFR therapy in colorectal cancer. Nature 486:532-536
-
(2012)
Nature
, vol.486
, pp. 532-536
-
-
Misale, S.1
Yaeger, R.2
Hobor, S.3
Scala, E.4
Janakiraman, M.5
Liska, D.6
Valtorta, E.7
Schiavo, R.8
Buscarino, M.9
Siravegna, G.10
Bencardino, K.11
Cercek, A.12
Chen, C.T.13
Veronese, S.14
Zanon, C.15
Sartore-Bianchi, A.16
Gambacorta, M.17
Gallicchio, M.18
Vakiani, E.19
Boscaro, V.20
Medico, E.21
Weiser, M.22
Siena, S.23
Di Nicolantonio, F.24
Solit, D.25
Bardelli, A.26
more..
-
72
-
-
22244472992
-
Poor survival associated with the BRAF V600E mutation in microsatellite-stable colon cancers
-
16024606 10.1158/0008-5472.CAN-05-0404 1:CAS:528:DC%2BD2MXmt1ehtLY%3D
-
Samowitz WS, Sweeney C, Herrick J, Albertsen H, Levin TR, Murtaugh MA, Wolff RK, Slattery ML (2005) Poor survival associated with the BRAF V600E mutation in microsatellite-stable colon cancers. Cancer Res 65:6063-6069
-
(2005)
Cancer Res
, vol.65
, pp. 6063-6069
-
-
Samowitz, W.S.1
Sweeney, C.2
Herrick, J.3
Albertsen, H.4
Levin, T.R.5
Murtaugh, M.A.6
Wolff, R.K.7
Slattery, M.L.8
-
73
-
-
57449095367
-
Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer
-
19001320 10.1200/JCO.2008.18.0786
-
Di Nicolantonio F, Martini M, Molinari F, Sartore-Bianchi A, Arena S, Saletti P, De Dosso S, Mazzucchelli L, Frattini M, Siena S, Bardelli A (2008) Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer. J Clin Oncol 26:5705-5712
-
(2008)
J Clin Oncol
, vol.26
, pp. 5705-5712
-
-
Di Nicolantonio, F.1
Martini, M.2
Molinari, F.3
Sartore-Bianchi, A.4
Arena, S.5
Saletti, P.6
De Dosso, S.7
Mazzucchelli, L.8
Frattini, M.9
Siena, S.10
Bardelli, A.11
-
74
-
-
84862026304
-
Addition of cetuximab to chemotherapy as first-line treatment for KRAS wild-type metastatic colorectal cancer: Pooled analysis of the CRYSTAL and OPUS randomised clinical trials
-
22446022 10.1016/j.ejca.2012.02.057 1:CAS:528:DC%2BC38XkvFSlsro%3D
-
Bokemeyer C, Cutsem EV, Rougier P, Ciardiello F, Heeger S, Schlichting M, Celik I, Kohne CH (2012) Addition of cetuximab to chemotherapy as first-line treatment for KRAS wild-type metastatic colorectal cancer: pooled analysis of the CRYSTAL and OPUS randomised clinical trials. Eur J Cancer 48:1466-1475
-
(2012)
Eur J Cancer
, vol.48
, pp. 1466-1475
-
-
Bokemeyer, C.1
Cutsem, E.V.2
Rougier, P.3
Ciardiello, F.4
Heeger, S.5
Schlichting, M.6
Celik, I.7
Kohne, C.H.8
-
75
-
-
18644378618
-
A role for K-ras in conferring resistance to the MEK inhibitor, CI-1040
-
15967111 10.1593/neo.04532 1:CAS:528:DC%2BD2MXkvFeqtL0%3D
-
Wang Y, Van Becelaere K, Jiang P, Przybranowski S, Omer C, Sebolt-Leopold J (2005) A role for K-ras in conferring resistance to the MEK inhibitor, CI-1040. Neoplasia 7:336-347
-
(2005)
Neoplasia
, vol.7
, pp. 336-347
-
-
Wang, Y.1
Van Becelaere, K.2
Jiang, P.3
Przybranowski, S.4
Omer, C.5
Sebolt-Leopold, J.6
-
76
-
-
79953240219
-
Amplification of the driving oncogene, KRAS or BRAF, underpins acquired resistance to MEK1/2 inhibitors in colorectal cancer cells
-
Little AS, Balmanno K, Sale MJ, Newman S, Dry JR, Hampson M, Edwards PA, Smith PD, Cook SJ (2011) Amplification of the driving oncogene, KRAS or BRAF, underpins acquired resistance to MEK1/2 inhibitors in colorectal cancer cells. Sci Signal ra4:17
-
(2011)
Sci Signal
, vol.4
, pp. 17
-
-
Little, A.S.1
Balmanno, K.2
Sale, M.J.3
Newman, S.4
Dry, J.R.5
Hampson, M.6
Edwards, P.A.7
Smith, P.D.8
Cook, S.J.9
-
77
-
-
78650465237
-
Identification of predictive markers of response to the MEK1/2 inhibitor selumetinib (AZD6244) in K-ras-mutated colorectal cancer
-
20923857 10.1158/1535-7163.MCT-10-0376 1:CAS:528:DC%2BC3cXhsFGrsLvM
-
Tentler JJ, Nallapareddy S, Tan AC, Spreafico A, Pitts TM, Morelli MP, Selby HM, Kachaeva MI, Flanigan SA, Kulikowski GN, Leong S, Arcaroli JJ, Messersmith WA, Eckhardt SG (2010) Identification of predictive markers of response to the MEK1/2 inhibitor selumetinib (AZD6244) in K-ras-mutated colorectal cancer. Mol Cancer Ther 9:3351-3362
-
(2010)
Mol Cancer Ther
, vol.9
, pp. 3351-3362
-
-
Tentler, J.J.1
Nallapareddy, S.2
Tan, A.C.3
Spreafico, A.4
Pitts, T.M.5
Morelli, M.P.6
Selby, H.M.7
Kachaeva, M.I.8
Flanigan, S.A.9
Kulikowski, G.N.10
Leong, S.11
Arcaroli, J.J.12
Messersmith, W.A.13
Eckhardt, S.G.14
-
78
-
-
77956280407
-
PIK3CA mutation uncouples tumor growth and cyclin D1 regulation from MEK/ERK and mutant KRAS signaling
-
20699365 10.1158/0008-5472.CAN-10-0409 1:CAS:528:DC%2BC3cXhtV2rsLbJ
-
Halilovic E, She QB, Ye Q, Pagliarini R, Sellers WR, Solit DB, Rosen N (2010) PIK3CA mutation uncouples tumor growth and cyclin D1 regulation from MEK/ERK and mutant KRAS signaling. Cancer Res 70:6804-6814
-
(2010)
Cancer Res
, vol.70
, pp. 6804-6814
-
-
Halilovic, E.1
She, Q.B.2
Ye, Q.3
Pagliarini, R.4
Sellers, W.R.5
Solit, D.B.6
Rosen, N.7
-
79
-
-
70349878470
-
Intrinsic resistance to the MEK1/2 inhibitor AZD6244 (ARRY-142886) is associated with weak ERK1/2 signalling and/or strong PI3K signalling in colorectal cancer cell lines
-
19637312 10.1002/ijc.24604 1:CAS:528:DC%2BD1MXhtFOkt77K
-
Balmanno K, Chell SD, Gillings AS, Hayat S, Cook SJ (2009) Intrinsic resistance to the MEK1/2 inhibitor AZD6244 (ARRY-142886) is associated with weak ERK1/2 signalling and/or strong PI3K signalling in colorectal cancer cell lines. Int J Cancer 125:2332-2341
-
(2009)
Int J Cancer
, vol.125
, pp. 2332-2341
-
-
Balmanno, K.1
Chell, S.D.2
Gillings, A.S.3
Hayat, S.4
Cook, S.J.5
-
80
-
-
44449133319
-
PIK3CA mutation in colorectal cancer: Relationship with genetic and epigenetic alterations
-
18516290 1:CAS:528:DC%2BD1cXoslWgtLc%3D
-
Nosho K, Kawasaki T, Ohnishi M, Suemoto Y, Kirkner GJ, Zepf D, Yan L, Longtine JA, Fuchs CS, Ogino S (2008) PIK3CA mutation in colorectal cancer: relationship with genetic and epigenetic alterations. Neoplasia 10:534-541
-
(2008)
Neoplasia
, vol.10
, pp. 534-541
-
-
Nosho, K.1
Kawasaki, T.2
Ohnishi, M.3
Suemoto, Y.4
Kirkner, G.J.5
Zepf, D.6
Yan, L.7
Longtine, J.A.8
Fuchs, C.S.9
Ogino, S.10
-
81
-
-
50949104555
-
Response and determinants of cancer cell susceptibility to PI3K inhibitors: Combined targeting of PI3K and Mek1 as an effective anticancer strategy
-
18059185
-
Yu K, Toral-Barza L, Shi C, Zhang WG, Zask A (2008) Response and determinants of cancer cell susceptibility to PI3K inhibitors: combined targeting of PI3K and Mek1 as an effective anticancer strategy. Cancer Biol Ther 7:307-315
-
(2008)
Cancer Biol Ther
, vol.7
, pp. 307-315
-
-
Yu, K.1
Toral-Barza, L.2
Shi, C.3
Zhang, W.G.4
Zask, A.5
-
82
-
-
84859645779
-
The synergistic interaction of MEK and PI3K inhibitors is modulated by mTOR inhibition
-
22415236 10.1038/bjc.2012.70 1:CAS:528:DC%2BC38XlsFSktLg%3D
-
Haagensen EJ, Kyle S, Beale GS, Maxwell RJ, Newell DR (2012) The synergistic interaction of MEK and PI3K inhibitors is modulated by mTOR inhibition. Br J Cancer 106:1386-1394
-
(2012)
Br J Cancer
, vol.106
, pp. 1386-1394
-
-
Haagensen, E.J.1
Kyle, S.2
Beale, G.S.3
Maxwell, R.J.4
Newell, D.R.5
-
83
-
-
84860540538
-
Inhibition of MEK and PI3K/mTOR suppresses tumor growth but does not cause tumor regression in patient-derived xenografts of RAS-mutant colorectal carcinomas
-
22392911 10.1158/1078-0432.CCR-11-2683 1:CAS:528:DC%2BC38XmsFeju70%3D
-
Migliardi G, Sassi F, Torti D, Galimi F, Zanella ER, Buscarino M, Ribero D, Muratore A, Massucco P, Pisacane A, Risio M, Capussotti L, Marsoni S, Di Nicolantonio F, Bardelli A, Comoglio PM, Trusolino L, Bertotti A (2012) Inhibition of MEK and PI3K/mTOR suppresses tumor growth but does not cause tumor regression in patient-derived xenografts of RAS-mutant colorectal carcinomas. Clin Cancer Res 18:2515-2525
-
(2012)
Clin Cancer Res
, vol.18
, pp. 2515-2525
-
-
Migliardi, G.1
Sassi, F.2
Torti, D.3
Galimi, F.4
Zanella, E.R.5
Buscarino, M.6
Ribero, D.7
Muratore, A.8
Massucco, P.9
Pisacane, A.10
Risio, M.11
Capussotti, L.12
Marsoni, S.13
Di Nicolantonio, F.14
Bardelli, A.15
Comoglio, P.M.16
Trusolino, L.17
Bertotti, A.18
-
84
-
-
80053168788
-
Rethinking ovarian cancer: Recommendations for improving outcomes
-
21941283 10.1038/nrc3144 1:CAS:528:DC%2BC3MXht1ajurnM
-
Vaughan S, Coward JI, Bast RC Jr, Berchuck A, Berek JS, Brenton JD, Coukos G, Crum CC, Drapkin R, Etemadmoghadam D, Friedlander M, Gabra H, Kaye SB, Lord CJ, Lengyel E, Levine DA, McNeish IA, Menon U, Mills GB, Nephew KP, Oza AM, Sood AK, Stronach EA, Walczak H, Bowtell DD, Balkwill FR (2011) Rethinking ovarian cancer: recommendations for improving outcomes. Nat Rev Cancer 11:719-725
-
(2011)
Nat Rev Cancer
, vol.11
, pp. 719-725
-
-
Vaughan, S.1
Coward, J.I.2
Bast, Jr.R.C.3
Berchuck, A.4
Berek, J.S.5
Brenton, J.D.6
Coukos, G.7
Crum, C.C.8
Drapkin, R.9
Etemadmoghadam, D.10
Friedlander, M.11
Gabra, H.12
Kaye, S.B.13
Lord, C.J.14
Lengyel, E.15
Levine, D.A.16
McNeish, I.A.17
Menon, U.18
Mills, G.B.19
Nephew, K.P.20
Oza, A.M.21
Sood, A.K.22
Stronach, E.A.23
Walczak, H.24
Bowtell, D.D.25
Balkwill, F.R.26
more..
-
85
-
-
79959328816
-
Molecular pathogenesis and extraovarian origin of epithelial ovarian cancer-shifting the paradigm
-
21683865 10.1016/j.humpath.2011.03.003 1:CAS:528:DC%2BC3MXnslehtbo%3D
-
Kurman RJ, Shih I (2011) Molecular pathogenesis and extraovarian origin of epithelial ovarian cancer-shifting the paradigm. Hum Pathol 42:918-931
-
(2011)
Hum Pathol
, vol.42
, pp. 918-931
-
-
Kurman, R.J.1
Shih, I.2
-
86
-
-
1942469352
-
Ovarian tumorigenesis: A proposed model based on morphological and molecular genetic analysis
-
15111296 10.1016/S0002-9440(10)63708-X 1:CAS:528:DC%2BD2cXns1Gqtb0%3D
-
Shih I, Kurman RJ (2004) Ovarian tumorigenesis: a proposed model based on morphological and molecular genetic analysis. Am J Pathol 164:1511-1518
-
(2004)
Am J Pathol
, vol.164
, pp. 1511-1518
-
-
Shih, I.1
Kurman, R.J.2
-
87
-
-
84878654846
-
A phase II trial of selumetinib in women with recurrent low-grade serous carcinoma of the ovary or peritoneum
-
Abstracts:CT-05
-
Farley J, Brady W, Birrer M, Lankes H, Coleman R, Morgan M, Mannel R, Yamada D, Mutch D, Rodgers W, Gershenson D (2012) A phase II trial of selumetinib in women with recurrent low-grade serous carcinoma of the ovary or peritoneum. AACR Meeting Abstracts:CT-05
-
(2012)
AACR Meeting
-
-
Farley, J.1
Brady, W.2
Birrer, M.3
Lankes, H.4
Coleman, R.5
Morgan, M.6
Mannel, R.7
Yamada, D.8
Mutch, D.9
Rodgers, W.10
Gershenson, D.11
-
88
-
-
80051584382
-
In vivo activity of combined PI3K/mTOR and MEK inhibition in a Kras(G12D); Pten deletion mouse model of ovarian cancer
-
21632463 10.1158/1535-7163.MCT-11-0240 1:CAS:528:DC%2BC3MXhtFSqtLbP
-
Kinross KM, Brown DV, Kleinschmidt M, Jackson S, Christensen J, Cullinane C, Hicks RJ, Johnstone RW, McArthur GA (2011) In vivo activity of combined PI3K/mTOR and MEK inhibition in a Kras(G12D); Pten deletion mouse model of ovarian cancer. Mol Cancer Ther 10:1440-1449
-
(2011)
Mol Cancer Ther
, vol.10
, pp. 1440-1449
-
-
Kinross, K.M.1
Brown, D.V.2
Kleinschmidt, M.3
Jackson, S.4
Christensen, J.5
Cullinane, C.6
Hicks, R.J.7
Johnstone, R.W.8
McArthur, G.A.9
-
89
-
-
0027733796
-
K-ras oncogene activation in adenocarcinoma of the human pancreas. A study of 82 carcinomas using a combination of mutant-enriched polymerase chain reaction analysis and allele-specific oligonucleotide hybridization
-
8342602 1:STN:280:DyaK3szktlaisA%3D%3D
-
Hruban RH, van Mansfeld AD, Offerhaus GJ, van Weering DH, Allison DC, Goodman SN, Kensler TW, Bose KK, Cameron JL, Bos JL (1993) K-ras oncogene activation in adenocarcinoma of the human pancreas. A study of 82 carcinomas using a combination of mutant-enriched polymerase chain reaction analysis and allele-specific oligonucleotide hybridization. Am J Pathol 143:545-554
-
(1993)
Am J Pathol
, vol.143
, pp. 545-554
-
-
Hruban, R.H.1
Van Mansfeld, A.D.2
Offerhaus, G.J.3
Van Weering, D.H.4
Allison, D.C.5
Goodman, S.N.6
Kensler, T.W.7
Bose, K.K.8
Cameron, J.L.9
Bos, J.L.10
-
90
-
-
80054000816
-
Impact of KRAS mutations on clinical outcomes in pancreatic cancer patients treated with first-line gemcitabine-based chemotherapy
-
21862683 10.1158/1535-7163.MCT-11-0269 1:CAS:528:DC%2BC3MXht1yls7%2FL
-
Kim ST, Lim do H, Jang KT, Lim T, Lee J, Choi YL, Jang HL, Yi JH, Baek KK, Park SH, Park YS, Lim HY, Kang WK, Park JO (2011) Impact of KRAS mutations on clinical outcomes in pancreatic cancer patients treated with first-line gemcitabine-based chemotherapy. Mol Cancer Ther 10:1993-1999
-
(2011)
Mol Cancer Ther
, vol.10
, pp. 1993-1999
-
-
Kim, S.T.1
Lim Do, H.2
Jang, K.T.3
Lim, T.4
Lee, J.5
Choi, Y.L.6
Jang, H.L.7
Yi, J.H.8
Baek, K.K.9
Park, S.H.10
Park, Y.S.11
Lim, H.Y.12
Kang, W.K.13
Park, J.O.14
-
91
-
-
84863012865
-
Oncogenic Kras is required for both the initiation and maintenance of pancreatic cancer in mice
-
22232209 10.1172/JCI59227 1:CAS:528:DC%2BC38XitVelsrc%3D
-
Collins MA, Bednar F, Zhang Y, Brisset JC, Galban S, Galban CJ, Rakshit S, Flannagan KS, Adsay NV, di Magliano M (2012) Oncogenic Kras is required for both the initiation and maintenance of pancreatic cancer in mice. J Clin Invest 122:639-653
-
(2012)
J Clin Invest
, vol.122
, pp. 639-653
-
-
Collins, M.A.1
Bednar, F.2
Zhang, Y.3
Brisset, J.C.4
Galban, S.5
Galban, C.J.6
Rakshit, S.7
Flannagan, K.S.8
Adsay, N.V.9
Di Magliano, M.10
-
92
-
-
77954675751
-
Inhibition of PI3K/AKT and MAPK/ERK pathways causes activation of FOXO transcription factor, leading to cell cycle arrest and apoptosis in pancreatic cancer
-
20642839 10.1186/1750-2187-5-10
-
Roy SK, Srivastava RK, Shankar S (2010) Inhibition of PI3K/AKT and MAPK/ERK pathways causes activation of FOXO transcription factor, leading to cell cycle arrest and apoptosis in pancreatic cancer. J Mol Signal 5:10
-
(2010)
J Mol Signal
, vol.5
, pp. 10
-
-
Roy, S.K.1
Srivastava, R.K.2
Shankar, S.3
-
93
-
-
23944439944
-
Phase i and pharmacodynamic study of the oral MEK inhibitor CI-1040 in patients with advanced malignancies
-
16009947 10.1200/JCO.2005.14.415 1:CAS:528:DC%2BD2MXpslOrtL8%3D
-
Lorusso PM, Adjei AA, Varterasian M, Gadgeel S, Reid J, Mitchell DY, Hanson L, DeLuca P, Bruzek L, Piens J, Asbury P, Van Becelaere K, Herrera R, Sebolt-Leopold J, Meyer MB (2005) Phase I and pharmacodynamic study of the oral MEK inhibitor CI-1040 in patients with advanced malignancies. J Clin Oncol 23:5281-5293
-
(2005)
J Clin Oncol
, vol.23
, pp. 5281-5293
-
-
Lorusso, P.M.1
Adjei, A.A.2
Varterasian, M.3
Gadgeel, S.4
Reid, J.5
Mitchell, D.Y.6
Hanson, L.7
Deluca, P.8
Bruzek, L.9
Piens, J.10
Asbury, P.11
Van Becelaere, K.12
Herrera, R.13
Sebolt-Leopold, J.14
Meyer, M.B.15
-
94
-
-
0035845511
-
Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications
-
11553815 10.1073/pnas.191367098 1:CAS:528:DC%2BD3MXntVGmsbo%3D
-
Sorlie T, Perou CM, Tibshirani R, Aas T, Geisler S, Johnsen H, Hastie T, Eisen MB, van de Rijn M, Jeffrey SS, Thorsen T, Quist H, Matese JC, Brown PO, Botstein D, Lonning PE, Borresen-Dale AL (2001) Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci USA 98:10869-10874
-
(2001)
Proc Natl Acad Sci USA
, vol.98
, pp. 10869-10874
-
-
Sorlie, T.1
Perou, C.M.2
Tibshirani, R.3
Aas, T.4
Geisler, S.5
Johnsen, H.6
Hastie, T.7
Eisen, M.B.8
Van De Rijn, M.9
Jeffrey, S.S.10
Thorsen, T.11
Quist, H.12
Matese, J.C.13
Brown, P.O.14
Botstein, D.15
Lonning, P.E.16
Borresen-Dale, A.L.17
-
95
-
-
79151476662
-
Triple negative breast cancer: Unmet medical needs
-
21161370 10.1007/s10549-010-1293-1 1:CAS:528:DC%2BC3MXhtVelsbw%3D
-
Pal SK, Childs BH, Pegram M (2011) Triple negative breast cancer: unmet medical needs. Breast Cancer Res Treat 125:627-636
-
(2011)
Breast Cancer Res Treat
, vol.125
, pp. 627-636
-
-
Pal, S.K.1
Childs, B.H.2
Pegram, M.3
-
96
-
-
84868201628
-
Rare oncogenic mutations of predictive markers for targeted therapy in triple-negative breast cancer
-
22610646 10.1007/s10549-012-2092-7 1:CAS:528:DC%2BC38XhtVOhsb7M
-
Grob TJ, Heilenkotter U, Geist S, Paluchowski P, Wilke C, Jaenicke F, Quaas A, Wilczak W, Choschzick M, Sauter G, Lebeau A (2012) Rare oncogenic mutations of predictive markers for targeted therapy in triple-negative breast cancer. Breast Cancer Res Treat 134:561-567
-
(2012)
Breast Cancer Res Treat
, vol.134
, pp. 561-567
-
-
Grob, T.J.1
Heilenkotter, U.2
Geist, S.3
Paluchowski, P.4
Wilke, C.5
Jaenicke, F.6
Quaas, A.7
Wilczak, W.8
Choschzick, M.9
Sauter, G.10
Lebeau, A.11
-
97
-
-
68049085887
-
In vivo antitumor activity of MEK and phosphatidylinositol 3-kinase inhibitors in basal-like breast cancer models
-
19567590 10.1158/1078-0432.CCR-09-0317 1:CAS:528:DC%2BD1MXosV2ltLo%3D
-
Hoeflich KP, O'Brien C, Boyd Z, Cavet G, Guerrero S, Jung K, Januario T, Savage H, Punnoose E, Truong T, Zhou W, Berry L, Murray L, Amler L, Belvin M, Friedman LS, Lackner MR (2009) In vivo antitumor activity of MEK and phosphatidylinositol 3-kinase inhibitors in basal-like breast cancer models. Clin Cancer Res 15:4649-4664
-
(2009)
Clin Cancer Res
, vol.15
, pp. 4649-4664
-
-
Hoeflich, K.P.1
O'Brien, C.2
Boyd, Z.3
Cavet, G.4
Guerrero, S.5
Jung, K.6
Januario, T.7
Savage, H.8
Punnoose, E.9
Truong, T.10
Zhou, W.11
Berry, L.12
Murray, L.13
Amler, L.14
Belvin, M.15
Friedman, L.S.16
Lackner, M.R.17
-
98
-
-
58349091262
-
Basal subtype and MAPK/ERK kinase (MEK)-phosphoinositide 3-kinase feedback signaling determine susceptibility of breast cancer cells to MEK inhibition
-
19147570 10.1158/0008-5472.CAN-08-3389 1:CAS:528:DC%2BD1MXltFShsA%3D%3D
-
Mirzoeva OK, Das D, Heiser LM, Bhattacharya S, Siwak D, Gendelman R, Bayani N, Wang NJ, Neve RM, Guan Y, Hu Z, Knight Z, Feiler HS, Gascard P, Parvin B, Spellman PT, Shokat KM, Wyrobek AJ, Bissell MJ, McCormick F, Kuo WL, Mills GB, Gray JW, Korn WM (2009) Basal subtype and MAPK/ERK kinase (MEK)-phosphoinositide 3-kinase feedback signaling determine susceptibility of breast cancer cells to MEK inhibition. Cancer Res 69:565-572
-
(2009)
Cancer Res
, vol.69
, pp. 565-572
-
-
Mirzoeva, O.K.1
Das, D.2
Heiser, L.M.3
Bhattacharya, S.4
Siwak, D.5
Gendelman, R.6
Bayani, N.7
Wang, N.J.8
Neve, R.M.9
Guan, Y.10
Hu, Z.11
Knight, Z.12
Feiler, H.S.13
Gascard, P.14
Parvin, B.15
Spellman, P.T.16
Shokat, K.M.17
Wyrobek, A.J.18
Bissell, M.J.19
McCormick, F.20
Kuo, W.L.21
Mills, G.B.22
Gray, J.W.23
Korn, W.M.24
more..
-
99
-
-
84919781694
-
Combined PI3K and MEK inhibition in patient-derived xenografts generated from recurrent triple negative breast cancer
-
[abstract 648]
-
Ibrahim YH, Serra V, Scaltriti M, Prudkin L, Anton P, Perez J, Balmana J, Baselga J (2011) Combined PI3K and MEK inhibition in patient-derived xenografts generated from recurrent triple negative breast cancer. In: Proceedings of the 102nd annual meeting of the American Association for Cancer Research:[abstract 648]
-
(2011)
Proceedings of the 102nd Annual Meeting of the American Association for Cancer Research
-
-
Ibrahim, Y.H.1
Serra, V.2
Scaltriti, M.3
Prudkin, L.4
Anton, P.5
Perez, J.6
Balmana, J.7
Baselga, J.8
-
100
-
-
84871183627
-
A first-in-human phase Ib study to evaluate the MEK inhibitor GDC-0973, combined with the pan-PI3K inhibitor GDC-0941
-
LoRusso P, Shapiro G, Pandya SS, Kwak EL, Jones C, Belvin M, Musib LC, de Crespigny A, McKenzie M, Gates MR, Chan IT, Bendell JC (2012) A first-in-human phase Ib study to evaluate the MEK inhibitor GDC-0973, combined with the pan-PI3K inhibitor GDC-0941, in patients with advanced solid tumors. ASCO Meeting Abstracts 30:2566
-
(2012)
Patients with Advanced Solid Tumors. ASCO Meeting Abstracts
, vol.30
, pp. 2566
-
-
Lorusso, P.1
Shapiro, G.2
Pandya, S.S.3
Kwak, E.L.4
Jones, C.5
Belvin, M.6
Musib, L.C.7
De Crespigny, A.8
McKenzie, M.9
Gates, M.R.10
Chan, I.T.11
Bendell, J.C.12
-
101
-
-
84867073064
-
A phase lb, open-label, multicenter, dose-escalation study of the oral
-
Bedard P, Tabernero J, Kurzrock R, Britten CD, Stathis A, Perez-Garcia JM, Zubel A, Le NT, Carter K, Bellew KM, Gallarati C, Niazi F, Demanse D, De Buck SS, Sessa C (2012) A phase lb, open-label, multicenter, dose-escalation study of the oral pan-PI3K inhibitor BKM120 in combination with the oral MEK1/2 inhibitor GSK1120212 in patients (pts) with selected advanced solid tumors. ASCO Meeting Abstracts 30:3003
-
(2012)
ASCO Meeting Abstracts
, vol.30
, pp. 3003
-
-
Bedard, P.1
Tabernero, J.2
Kurzrock, R.3
Britten, C.D.4
Stathis, A.5
Perez-Garcia, J.M.6
Zubel, A.7
Le, N.T.8
Carter, K.9
Bellew, K.M.10
Gallarati, C.11
Niazi, F.12
Demanse, D.13
De Buck, S.S.14
Sessa, C.15
-
102
-
-
84878642347
-
A Multi-arm Phase 1 Dose Escalation Study of Safety, Pharmacokinetics, and Pharmacodynamics of the Dual PI3K/mTor Inhibitors PF-04691502 (oral) and PF-05212384 (IV) in Combination with the MEK Inhibitor PD-0325901 or Irinotecan in Patients with Advanced Cancer
-
Abstract 366
-
Britten C, Wainberg Z, Tabernero J, Alsina Maqueda M, Leong S, Sessa C, Millham R, Gallo J, Siu L, Brana I (2012) A Multi-arm Phase 1 Dose Escalation Study of Safety, Pharmacokinetics, and Pharmacodynamics of the Dual PI3K/mTor Inhibitors PF-04691502 (oral) and PF-05212384 (IV) in Combination with the MEK Inhibitor PD-0325901 or Irinotecan in Patients with Advanced Cancer. EORTC-NCI-AACR 2012 Abstract 366
-
(2012)
EORTC-NCI-AACR 2012
-
-
Britten, C.1
Wainberg, Z.2
Tabernero, J.3
Alsina Maqueda, M.4
Leong, S.5
Sessa, C.6
Millham, R.7
Gallo, J.8
Siu, L.9
Brana, I.10
-
103
-
-
84864340896
-
Safety, pharmacokinetic, pharmacodynamic, and efficacy data for the oral MEK inhibitor trametinib: A phase 1 dose-escalation trial
-
22805291 10.1016/S1470-2045(12)70270-X 1:CAS:528:DC%2BC38XhtFajsLvP
-
Infante JR, Fecher LA, Falchook GS, Nallapareddy S, Gordon MS, Becerra C, Demarini DJ, Cox DS, Xu Y, Morris SR, Peddareddigari VG, Le NT, Hart L, Bendell JC, Eckhardt G, Kurzrock R, Flaherty K, Burris HA 3rd, Messersmith WA (2012) Safety, pharmacokinetic, pharmacodynamic, and efficacy data for the oral MEK inhibitor trametinib: a phase 1 dose-escalation trial. Lancet Oncol 13:773-781
-
(2012)
Lancet Oncol
, vol.13
, pp. 773-781
-
-
Infante, J.R.1
Fecher, L.A.2
Falchook, G.S.3
Nallapareddy, S.4
Gordon, M.S.5
Becerra, C.6
Demarini, D.J.7
Cox, D.S.8
Xu, Y.9
Morris, S.R.10
Peddareddigari, V.G.11
Le, N.T.12
Hart, L.13
Bendell, J.C.14
Eckhardt, G.15
Kurzrock, R.16
Flaherty, K.17
Burris, H.A.18
Messersmith, W.A.19
-
104
-
-
84866623276
-
Ocular toxicity of targeted therapies
-
22649132 10.1200/JCO.2011.41.5851 1:CAS:528:DC%2BC38XhsVKrsL%2FL
-
Renouf DJ, Velazquez-Martin JP, Simpson R, Siu LL, Bedard PL (2012) Ocular toxicity of targeted therapies. J Clin Oncol 30:3277-3286
-
(2012)
J Clin Oncol
, vol.30
, pp. 3277-3286
-
-
Renouf, D.J.1
Velazquez-Martin, J.P.2
Simpson, R.3
Siu, L.L.4
Bedard, P.L.5
-
105
-
-
84866070768
-
Molecular profiling of patients with colorectal cancer and matched targeted therapy in phase i clinical trials
-
22723336 10.1158/1535-7163.MCT-12-0290 1:CAS:528:DC%2BC38XhtlWhsrnO
-
Dienstmann R, Serpico D, Rodon J, Saura C, Macarulla T, Elez E, Alsina M, Capdevila J, Perez-Garcia J, Sanchez-Olle G, Aura C, Prudkin L, Landolfi S, Hernandez-Losa J, Vivancos A, Tabernero J (2012) Molecular profiling of patients with colorectal cancer and matched targeted therapy in phase I clinical trials. Mol Cancer Ther 11:2062-2071
-
(2012)
Mol Cancer Ther
, vol.11
, pp. 2062-2071
-
-
Dienstmann, R.1
Serpico, D.2
Rodon, J.3
Saura, C.4
MacArulla, T.5
Elez, E.6
Alsina, M.7
Capdevila, J.8
Perez-Garcia, J.9
Sanchez-Olle, G.10
Aura, C.11
Prudkin, L.12
Landolfi, S.13
Hernandez-Losa, J.14
Vivancos, A.15
Tabernero, J.16
|